/**
 * Demographic landing page schema.
 *
 * Powers the /peptides-for/[slug] route. Each entry is a single SEO-targeted
 * page like "Peptides for Men Over 40" or "Peptides for Bodybuilders".
 *
 * Architecture: editorial authors a *prioritized goal list* per page. The
 * compound recommendations are DERIVED from the existing
 * GOAL_LIFE_STAGE_FIT + GOALS + PEPTIDE_AGE_GUIDANCE + PEPTIDE_SEX_GUIDANCE
 * tables. Pages never invent peptide picks — they declare which goals matter
 * for the audience and the data layer answers which compounds to surface.
 */

import type { AgeRange } from "@/types/planner";
import type { EditorialReview } from "@/lib/editorial";
import type { BlogFaq } from "./blog";
import { GOALS, getGoalById, type GoalData } from "./goals";
import { GOAL_LIFE_STAGE_FIT } from "./goal-life-stage-fit";
import {
  getAgeExclusionReason,
  getAgeCautionReason,
} from "./age-guidance";
import {
  getSexExclusionReason,
  getSexCautionReason,
} from "./sex-guidance";
import { getPeptideById, type PeptideData } from "./peptides";
import { getAffiliateUrlForVendor } from "./affiliate-links";

// ──────────────────────────────────────────────────────────────────────
// Types
// ──────────────────────────────────────────────────────────────────────

export type DemographicCluster =
  | "age-gender"
  | "life-stage"
  | "condition"
  | "athlete"
  | "aesthetic"
  | "goal"
  | "lifestyle"
  | "body-type"
  | "recovery"
  | "mental-health"
  | "safety";

export type DemographicSex = "male" | "female" | "any";

/** Mirrors the wider tier set used in the peptide DB. */
export type EvidenceTier = "A" | "B" | "B-C" | "C" | "C-D" | "D";
/** Mirrors the risk levels in the peptide DB. */
export type RiskLevel = "low" | "medium" | "med-high" | "high" | "extreme";

export interface DemographicSafetyFlag {
  label: string;
  detail: string;
  severity: "info" | "warning" | "danger";
}

export interface DemographicPriorityGoal {
  /** Must match a goal id in src/data/goals.ts */
  goalId: string;
  /** 1-sentence editorial: why this goal matters for this audience */
  framing: string;
}

export interface DemographicSiblingLink {
  slug: string;
  title: string;
  audience: string;
}

export interface DemographicBodySection {
  id: string;
  title: string;
  eyebrow?: string;
  paragraphs: string[];
  bullets?: string[];
}

export interface DemographicPageData {
  // identity
  id: string;
  slug: string;
  cluster: DemographicCluster;
  audience: string;
  audienceChips: string[];

  // demographic resolution (drives the derivation)
  /** Maps to AgeRange used by GOAL_LIFE_STAGE_FIT + age-guidance tables */
  ageRange: AgeRange | null;
  sex: DemographicSex;

  // seo
  seoTitle: string;
  seoDescription: string;
  h1: string;
  canonicalPath: string;
  primaryKeyword: string;
  ogImage?: string;
  editorialReview?: EditorialReview;
  /**
   * Name of the MedicalCondition this page is genuinely about, if any.
   * Only set on condition / life-stage pages where the audience IS the condition
   * (e.g. "Polycystic Ovary Syndrome", "Menopause"). Leave undefined for
   * demographic pages where the audience is not a medical condition
   * ("Men 60+" is not a condition — those pages get no MedicalCondition tag).
   * When set, DemographicJsonLd emits MedicalWebPage.about as a MedicalCondition.
   */
  medicalCondition?: string;

  // hero
  heroEyebrow: string;
  heroSummary: string;
  publishedAt: string;
  updatedAt: string;
  authorId: string;
  readMinutes: number;

  // above the fold
  tldr: string;
  safetyFlags: DemographicSafetyFlag[];

  // editorial only authors goals — peptides are derived
  /** 1–3 goals, ordered by priority */
  priorityGoals: DemographicPriorityGoal[];

  // narrative
  whyDifferent: {
    intro: string;
    points: string[];
  };
  bodySections: DemographicBodySection[];
  faqs: BlogFaq[];

  // hub linking
  siblings: DemographicSiblingLink[];
  relatedGoalIds?: string[];
  relatedPeptideIds?: string[];
}

export interface DemographicAuthor {
  id: string;
  name: string;
  credentials: string;
  bio: string;
  avatarPath?: string;
}

// ──────────────────────────────────────────────────────────────────────
// Derived compound recommendation
// ──────────────────────────────────────────────────────────────────────

export interface VendorLink {
  vendorId: "amino-club" | "xl-peptides";
  vendorName: string;
  url: string;
}

export interface DerivedPeptideRec {
  goalId: string;
  goalName: string;
  /** Editorial framing for why this goal matters to the audience */
  framing: string;
  peptide: PeptideData;
  /** Concise "why this compound" — pulled from goal-life-stage-fit note when present */
  rationale: string;
  /** Soft warning from age/sex guidance if applicable */
  caution?: string;
  vendorLinks: VendorLink[];
}

// ──────────────────────────────────────────────────────────────────────
// Authors
// ──────────────────────────────────────────────────────────────────────

export const DEMOGRAPHIC_AUTHORS: Record<string, DemographicAuthor> = {
  "research-desk": {
    id: "research-desk",
    name: "PeptidePros Research Desk",
    credentials: "Evidence team",
    bio: "Our research desk reviews peer-reviewed literature, clinical trials, and vendor COAs to produce every guide on this site. We are not a retailer.",
  },
};

// ──────────────────────────────────────────────────────────────────────
// Pages (content pipeline appends here)
// ──────────────────────────────────────────────────────────────────────

export const DEMOGRAPHIC_PAGES: DemographicPageData[] = [
  // ──────────────────────────────────────────────────────────────────
  // AGE × GENDER
  // ──────────────────────────────────────────────────────────────────
  {
    id: "men-in-their-20s",
    slug: "men-in-their-20s",
    cluster: "age-gender",
    audience: "Men 20–29",
    audienceChips: ["Male", "20–29", "Peak baseline"],
    ageRange: "25-34",
    sex: "male",
    seoTitle: "Peptides for Men in Their 20s (2026)",
    seoDescription:
      "What peptides actually do for men in their 20s — and what's overkill. Recovery and muscle support compounds matched to a 20-something male profile.",
    h1: "Peptides for Men in Their 20s",
    canonicalPath: "/blog/peptides-for/men-in-their-20s",
    primaryKeyword: "peptides for men in their 20s",
    heroEyebrow: "Demographic guide · Men 20–29",
    heroSummary:
      "Your 20s are your hormonal peak. Most peptides marketed to you are unnecessary. Two compounds — one to bank muscle, one for recovery — cover the actual evidence-backed cases.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 7,
    tldr: "Men in their 20s have peak endogenous growth hormone, testosterone, and recovery capacity. BPC-157 for soft-tissue injuries and a GH secretagogue for serious training blocks are the only compounds with a real case in this window.",
    safetyFlags: [
      {
        label: "GH peptides blunt your own production",
        detail: "Exogenous GH-axis compounds suppress your endogenous GH pulse during use. Cycle short, off long.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "muscle_growth", framing: "Banking muscle in your 20s pays compound interest for the next 40 years of training." },
      { goalId: "recovery", framing: "Soft-tissue injuries in your 20s are the ones that come back at 40 — heal them properly the first time." },
    ],
    whyDifferent: {
      intro: "A 20-something man's protocol should subtract, not add. You already have what most older men try to restore.",
      points: [
        "GH pulse amplitude peaks near age 21 and declines roughly 14% per decade after 30. You sit at the top of the curve.",
        "Total testosterone in men under 30 averages 600–700 ng/dL — well above the threshold for any libido, mood, or muscle complaint.",
        "Tendon turnover, satellite cell activity, and glycogen replenishment all peak in this window. Stack what you already have first.",
      ],
    },
    bodySections: [
      {
        id: "skip-list",
        eyebrow: "Skip list",
        title: "What men in their 20s should not run",
        paragraphs: [
          "Longevity peptides target biological clocks that have not started ticking. Sexual-health peptides target a problem most men this age do not have. GLP-1s in lean, active 20s men routinely cause excessive lean mass loss.",
        ],
        bullets: [
          "Epitalon, FOXO4-DRI — no clinical rationale at this age",
          "PT-141 — reserved for documented libido issues",
          "Semaglutide, tirzepatide — overkill unless clinically obese",
          "Tesamorelin — designed for HIV-associated lipodystrophy",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "The three situations that justify a peptide protocol",
        paragraphs: [
          "Most men in their 20s asking about peptides are bored, plateauing, or chasing the same edge their gym crowd is chasing. None of those are clinical indications. The cases where compounds genuinely earn their place at this age are narrow and concrete.",
          "Use this as a gate before opening any vendor tab: if your situation does not fit one of these three, the answer is to fix sleep, food, programming, and recovery before adding a research compound.",
        ],
        bullets: [
          "A documented soft-tissue injury (tendon, ligament, joint capsule) that has stalled in standard rehab — BPC-157 has the strongest research base for this single indication.",
          "A structured, time-bound gain phase (8–12 weeks) where training, calories, and sleep are already dialed in and a GH secretagogue is being added as the marginal lever — not the first lever.",
          "A clinical context — diagnosis-driven, supervised by a prescriber. Recovery from surgery, an inflammatory condition, an endocrine workup that returned an actionable result.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Protocol discipline at peak baseline",
        paragraphs: [
          "Because your endogenous system is already producing what older men try to recover, the dominant risk in your 20s is suppressing what you have. Short, deliberate cycles with longer breaks preserve the baseline you are starting from. Long open-ended use is what creates the dependency that older men present with at 40.",
        ],
        bullets: [
          "Run cycles, not regimens — 4–8 weeks on, at least equal time off, with a clear stop criterion before you start.",
          "One compound at a time during your first protocol — stacking obscures which input did what.",
          "Track sleep onset, morning resting heart rate, and morning erections weekly. Any drift past two weeks is a hold trigger, not a 'push through' moment.",
          "Get a baseline blood panel (CBC, CMP, fasting glucose, HbA1c, total testosterone, LH, FSH, IGF-1, lipids) before your first cycle so you have something to compare against.",
        ],
      },
      {
        id: "bridge-to-30s",
        eyebrow: "What changes next",
        title: "How the calculus shifts when you turn 30",
        paragraphs: [
          "The protocol you write at 28 is not the protocol that will serve you at 35. GH pulse amplitude begins its measurable decline in the early 30s, soft-tissue recovery margins narrow, and the first wave of stubborn body-composition complaints arrives. Your 20s are the window to bank the inputs — training history, sleep architecture, joint health — that make a 30s protocol meaningful instead of compensatory.",
        ],
        bullets: [
          "Compound priorities at 30+: GH-axis support shifts from optional to common; recovery peptides earn a more permanent role.",
          "Resistance-trained lean mass and bone density built in your 20s are the single largest determinant of how easy the next decade is.",
          "Read on once you cross 30:",
        ],
      },
    ],
    faqs: [
      {
        question: "Should I run peptides if I am already training and eating well?",
        answer: "For most men in their 20s, no. Training consistency, sleep, and protein intake produce more results than any peptide protocol at this age. Reserve compounds for specific situations: a documented soft-tissue injury, or a structured GH-secretagogue block during a focused gain phase.",
      },
      {
        question: "Will BPC-157 help with a tendonitis flare-up?",
        answer: "BPC-157 has the strongest tendon and soft-tissue evidence of any research peptide. A 4–6 week course at 250–500 mcg/day is the typical research dose for tendinopathy. It does not replace rehab and load management.",
      },
      {
        question: "Are GH secretagogues safer than testosterone?",
        answer: "They act on different axes. GH secretagogues (CJC-1295, ipamorelin) pulse growth hormone; they do not raise testosterone. The risk profile centers on water retention, mild glucose changes, and temporary suppression of your own GH pulse during use.",
      },
    ],
    siblings: [
      { slug: "men-in-their-30s", title: "Peptides for Men in Their 30s", audience: "Men 30–39" },
      { slug: "men-over-40", title: "Peptides for Men Over 40", audience: "Men 40–49" },
      { slug: "bodybuilders", title: "Peptides for Bodybuilders", audience: "Bodybuilders" },
      { slug: "students", title: "Peptides for Students", audience: "Students" },
    ],
    relatedGoalIds: ["muscle_growth", "recovery"],
  },

  {
    id: "men-in-their-30s",
    slug: "men-in-their-30s",
    cluster: "age-gender",
    audience: "Men 30–39",
    audienceChips: ["Male", "30–39", "Early decline"],
    ageRange: "35-44",
    sex: "male",
    seoTitle: "Peptides for Men in Their 30s (2026)",
    seoDescription:
      "Men 30–39 sit at the inflection point: GH and testosterone start declining, fat distribution shifts. Three compounds matched to muscle, fat loss, and recovery.",
    h1: "Peptides for Men in Their 30s",
    canonicalPath: "/blog/peptides-for/men-in-their-30s",
    primaryKeyword: "peptides for men in their 30s",
    heroEyebrow: "Demographic guide · Men 30–39",
    heroSummary:
      "The decade where GH pulses begin to thin out and visceral fat creeps up. Three compounds — one each for muscle retention, fat loss, and recovery — cover the actual midlife-onset cases.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Men in their 30s start losing roughly 1% of GH pulse amplitude per year and accumulate visceral fat independent of bodyweight. The high-evidence picks are a GH secretagogue for muscle, a GLP-1 for stubborn fat, and BPC-157 for the recovery margin you lose with training volume.",
    safetyFlags: [
      {
        label: "Get baseline labs first",
        detail: "Fasting glucose, lipid panel, IGF-1, and total testosterone before starting any GH-axis or GLP-1 compound.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "muscle_growth", framing: "Lean mass retention shifts from automatic to deliberate in your 30s — a GH-axis nudge restores the recovery margin." },
      { goalId: "fat_loss", framing: "Visceral fat accumulation accelerates independent of bodyweight, and GLP-1s have the strongest human evidence for this exact window." },
      { goalId: "recovery", framing: "Training volume gets heavier to fight a slower recovery curve — BPC-157 helps close the gap." },
    ],
    whyDifferent: {
      intro: "Your 30s are the decade where the cost of maintenance becomes visible. Small inputs now prevent large interventions at 50.",
      points: [
        "GH pulse amplitude declines ~14% per decade after 30, shrinking the overnight recovery window.",
        "Visceral fat begins accumulating independent of caloric intake, driven by cortisol and insulin-sensitivity shifts.",
        "Tendon and joint reserve start to feel finite — soft-tissue injuries take 2–3× longer to heal vs. a 22-year-old.",
      ],
    },
    bodySections: [
      {
        id: "labs-first",
        eyebrow: "Before you start",
        title: "Run labs before any compound",
        paragraphs: [
          "Baseline labs catch the issues that masquerade as 'just getting older.' Low testosterone, prediabetes, and hidden inflammation all change which compound is appropriate.",
        ],
        bullets: [
          "Total + free testosterone, SHBG, LH, FSH",
          "Fasting glucose, fasting insulin, HbA1c",
          "Comprehensive lipid panel including ApoB",
          "IGF-1 (baseline for GH-axis decisions)",
          "hs-CRP for systemic inflammation",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "The cases that justify a protocol in your 30s",
        paragraphs: [
          "Your 30s are the first decade where peptides have legitimate room to earn their place — but only when they are solving for a specific, measurable change. The mistake is starting compounds in response to a feeling. Anchor every decision to a number on a lab or a documented injury that has stalled.",
        ],
        bullets: [
          "A recurring soft-tissue issue (tendinopathy, joint capsule, post-surgical) that standard rehab has not resolved in 6–8 weeks — BPC-157 has the cleanest evidence here.",
          "Visceral fat or stubborn body-composition shifts that have resisted 12+ weeks of dialed-in diet and training — a GLP-1 enters the conversation, ideally clinician-supervised.",
          "Recovery markers (sleep architecture, morning HRV, training tolerance) trending poorly while baseline labs (T, IGF-1, fasting glucose) remain in range — a short GH-secretagogue block is reasonable.",
          "First labs show borderline-low free testosterone with symptoms — work the workup up to a clinician before reaching for peptides as a band-aid.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Protocol discipline as recovery margin narrows",
        paragraphs: [
          "The 30s rule is restraint plus measurement. The recovery cushion you had at 25 is half what it will be at 45, and protocol mistakes that were forgiven in your 20s now stick. Treat every compound as time-limited with a written stop criterion before the first dose.",
        ],
        bullets: [
          "Repeat your baseline labs every 6 months — not annually. Change is faster than at 25.",
          "Run GH-secretagogue blocks at 8–12 weeks on, 4 weeks off; do not stack a second GH-axis compound during the same block.",
          "If using a GLP-1, hold resistance training at or above pre-protocol volume and aim for 1 g/lb bodyweight protein to protect lean mass.",
          "Track weekly: sleep onset, morning resting HR, AM erection frequency, training session RPE. Any two trending poorly is a hold-and-reassess trigger.",
        ],
      },
      {
        id: "bridge-to-40s",
        eyebrow: "What changes next",
        title: "How the calculus shifts when you turn 40",
        paragraphs: [
          "Your 40s are when peptide protocols move from optional to common — but they also become inseparable from primary-care coordination. The cardiovascular and metabolic flags that simmered through your 30s start showing up on lipid panels and resting blood pressure. Compounds that were nice-to-have become risk-managed levers.",
        ],
        bullets: [
          "GH-axis support shifts from a periodic block to a more permanent recovery tool for most active men.",
          "Visceral fat, ApoB, fasting insulin, and resting blood pressure deserve quarterly attention, not annual.",
          "Coordinate every protocol with a primary-care or longevity clinician — solo experimentation gets riskier.",
          "Read on once you cross 40:",
        ],
      },
    ],
    faqs: [
      {
        question: "Is 35 too early to start peptides?",
        answer: "It depends on goals, not age. If you have a documented injury, declining recovery, or visceral fat that diet alone is not moving, a targeted compound has a case. If you are training consistently and recovering well, hold off.",
      },
      {
        question: "Do GLP-1s cause muscle loss in active men in their 30s?",
        answer: "All weight loss includes some lean mass loss. Active men who maintain high protein intake (~1g/lb bodyweight) and continued resistance training preserve significantly more lean mass on GLP-1s than sedentary users. Track DEXA or BIA if possible.",
      },
      {
        question: "Will I need to cycle off?",
        answer: "GH secretagogues are typically run in 8–12 week cycles with 4-week off periods to allow your endogenous pulse to recover. GLP-1s are dosed continuously while needed. BPC-157 is used in 4–6 week courses for specific injuries.",
      },
    ],
    siblings: [
      { slug: "men-in-their-20s", title: "Peptides for Men in Their 20s", audience: "Men 20–29" },
      { slug: "men-over-40", title: "Peptides for Men Over 40", audience: "Men 40–49" },
      { slug: "men-over-50", title: "Peptides for Men Over 50", audience: "Men 50–59" },
      { slug: "low-testosterone", title: "Peptides for Low Testosterone", audience: "Men with low T" },
    ],
    relatedGoalIds: ["muscle_growth", "fat_loss", "recovery"],
  },

  {
    id: "men-over-40",
    slug: "men-over-40",
    cluster: "age-gender",
    audience: "Men 40–49",
    audienceChips: ["Male", "40–49", "Midlife"],
    ageRange: "35-44",
    sex: "male",
    seoTitle: "Peptides for Men Over 40 (2026)",
    seoDescription:
      "Three compounds for men 40–49: GLP-1 for visceral fat, BPC-157 for recovery margin, PT-141 for libido. Matched to evidence and your decade.",
    h1: "Peptides for Men Over 40",
    canonicalPath: "/blog/peptides-for/men-over-40",
    primaryKeyword: "peptides for men over 40",
    heroEyebrow: "Demographic guide · Men 40–49",
    heroSummary:
      "The decade where visceral fat, joint reserve, and libido all start asking for attention at once. Three compounds — fat loss, recovery, sexual health — cover the dominant midlife signals.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Men 40–49 face three concurrent shifts: visceral fat resistant to diet, slowed soft-tissue recovery, and dipping libido. A GLP-1 for the metabolic shift, BPC-157 for recovery, and PT-141 for libido is the three-front protocol with the cleanest evidence.",
    safetyFlags: [
      {
        label: "Cancer history disqualifies GH-axis use",
        detail: "Active or recent malignancy is an absolute contraindication for any GH-axis peptide. Discuss with oncology.",
        severity: "danger",
      },
      {
        label: "Get bloodwork annually",
        detail: "Total/free T, IGF-1, glucose, ApoB, PSA. The numbers shift fastest in this decade.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "fat_loss", framing: "Visceral fat in your 40s is increasingly insulin-driven and responds disproportionately to incretin-class compounds." },
      { goalId: "recovery", framing: "Tendon and joint repair slow 2–3× from your 20s — recovery becomes a budget item, not a default." },
      { goalId: "sexual_health", framing: "Libido decline in your 40s is rarely about willpower; it tracks free T, sleep debt, and vascular health together." },
    ],
    whyDifferent: {
      intro: "The 40s are when 'getting older' stops being a metaphor. Three biological clocks tick at once, and they reinforce each other.",
      points: [
        "Total testosterone declines roughly 1–2% per year, with free T dropping faster as SHBG rises.",
        "Visceral fat accumulation drives insulin resistance, which suppresses libido and slows recovery — one input, three outputs.",
        "Deep sleep architecture compresses, reducing the overnight GH pulse that drives muscle and tendon repair.",
      ],
    },
    bodySections: [
      {
        id: "stacking-logic",
        eyebrow: "Protocol logic",
        title: "Why these three compounds together",
        paragraphs: [
          "Each compound addresses a distinct biological lever. A GLP-1 cuts visceral fat that drives insulin resistance. BPC-157 restores the soft-tissue recovery margin. PT-141 acts on the central nervous system pathway for arousal, which is independent of testosterone.",
          "None of these three compounds replaces TRT. If labs show low free testosterone, address that separately with a clinician — peptides do not raise endogenous testosterone meaningfully.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When to pull the trigger",
        title: "Indications that earn a protocol in your 40s",
        paragraphs: [
          "Forty is the decade where peptides graduate from optional to commonly indicated. The mistake is throwing compounds at vague malaise. Anchor each one to a specific number on a lab or a specific symptom with a measurable endpoint, and treat them as risk-managed levers rather than supplements.",
        ],
        bullets: [
          "Waist-to-height ratio above 0.5, fasting insulin >10, or ApoB above the age-adjusted range — incretin-class compounds enter the conversation.",
          "Free testosterone below the lower quartile for age with libido, mood, or recovery symptoms — work up TRT with a clinician first; peptides come second.",
          "Recurring tendinopathy, post-surgical recovery, or training-related soft-tissue injury that has stalled past 6 weeks of standard rehab.",
          "Documented sleep-architecture compression (poor deep sleep, low overnight HRV) where lifestyle inputs are dialed but recovery still fails.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline when the margin is thin",
        paragraphs: [
          "Your 40s are the decade where protocol mistakes have lasting cost. Stacking too many GH-axis compounds, riding GLP-1s without resistance training, or running anything without coordinating with primary care is how 40-year-old men present at 50 with iatrogenic problems. Build the protocol around your medical care, not around it.",
        ],
        bullets: [
          "Repeat baseline labs every 3 months during any active protocol; annual is too slow at this age.",
          "Coordinate every compound with a primary-care or longevity clinician — note interactions with statins, BP meds, and any pre-existing TRT.",
          "Resistance training at or above pre-protocol volume is non-negotiable on a GLP-1; otherwise expect meaningful lean mass loss.",
          "Cycle GH secretagogues 8–12 weeks on, 4 weeks off, and avoid stacking two GH-axis compounds in the same block.",
        ],
      },
      {
        id: "bridge-to-50s",
        eyebrow: "What changes next",
        title: "How the protocol changes when you turn 50",
        paragraphs: [
          "Your 50s shift the protocol from active intervention to active maintenance. Cardiovascular and metabolic flags rise into the foreground. The compounds that earn space have to demonstrate they reduce risk — recovery, longevity-leaning, cognitive — and the ones that push growth signaling start to come off the menu.",
        ],
        bullets: [
          "ApoB, fasting insulin, and PSA become standing quarterly metrics; HRV and resting HR earn weekly attention.",
          "GH-axis compounds shift from a permanent recovery tool back toward shorter, more deliberate blocks.",
          "Bone density baseline (DEXA scan) becomes a real input — falls and fractures are the silent risk multiplier of the next two decades.",
          "Read on once you cross 50:",
        ],
      },
    ],
    faqs: [
      {
        question: "Will peptides replace TRT?",
        answer: "No. The compounds matched to men 40–49 act on growth hormone, soft tissue, and arousal pathways — none meaningfully raise testosterone. If labs confirm low T, address that separately. Peptides and TRT can coexist; one does not substitute for the other.",
      },
      {
        question: "Do I need to lose weight before starting a GLP-1?",
        answer: "GLP-1s are evidence-backed across the BMI range from overweight (27+) up. If your BMI is in the healthy range but your waist-to-height ratio is elevated, that suggests visceral adiposity and many clinicians still find them appropriate.",
      },
      {
        question: "Can I run all three at the same time?",
        answer: "Yes — they target different pathways and have no documented interactions among themselves. A typical sequencing: start the GLP-1 first (4-week titration), add BPC-157 in cycles when training load is heavy, and use PT-141 acutely as needed.",
      },
      {
        question: "What labs do I need before starting?",
        answer: "Total and free testosterone, SHBG, fasting glucose, HbA1c, fasting insulin, comprehensive lipid panel including ApoB, IGF-1, and PSA. Repeat at 12 weeks to track response.",
      },
    ],
    siblings: [
      { slug: "men-in-their-30s", title: "Peptides for Men in Their 30s", audience: "Men 30–39" },
      { slug: "men-over-50", title: "Peptides for Men Over 50", audience: "Men 50–59" },
      { slug: "low-testosterone", title: "Peptides for Low Testosterone", audience: "Men with low T" },
      { slug: "obesity", title: "Peptides for Obesity", audience: "Obese adults" },
    ],
    relatedGoalIds: ["fat_loss", "recovery", "sexual_health"],
  },

  {
    id: "men-over-50",
    slug: "men-over-50",
    cluster: "age-gender",
    audience: "Men 50–59",
    audienceChips: ["Male", "50–59", "Anti-aging focus"],
    ageRange: "45-54",
    sex: "male",
    seoTitle: "Peptides for Men Over 50 (2026)",
    seoDescription:
      "Three compounds for men 50–59: longevity-focused anti-aging support, libido restoration, and joint recovery. Evidence-graded and matched to the decade.",
    h1: "Peptides for Men Over 50",
    canonicalPath: "/blog/peptides-for/men-over-50",
    primaryKeyword: "peptides for men over 50",
    heroEyebrow: "Demographic guide · Men 50–59",
    heroSummary:
      "Maintenance becomes the project. Three compounds — longevity, libido, recovery — address the dominant signals of the decade without overshooting.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Men 50–59 see GH down ~30% from peak, testosterone trending toward symptomatic ranges, and libido often the first complaint. A longevity-leaning anti-aging compound, PT-141 for libido, and BPC-157 for joint recovery is the conservative three-front protocol.",
    safetyFlags: [
      {
        label: "Screen for prostate and cardiac history",
        detail: "Any active prostate issue or recent cardiac event changes the calculus for GH-axis and arousal compounds.",
        severity: "danger",
      },
      {
        label: "Full annual physical with imaging",
        detail: "Cancer screening becomes non-optional this decade — GH-axis compounds amplify any undiagnosed growth signal.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "anti_aging", framing: "The shift from performance to maintenance — longevity-leaning compounds with the cleanest safety profile come forward." },
      { goalId: "sexual_health", framing: "Libido is the canary signal of vascular and hormonal health combined; addressing it touches multiple systems." },
      { goalId: "recovery", framing: "Joint reserve dictates how active you remain in your 60s and 70s — protecting it now is a long-horizon decision." },
    ],
    whyDifferent: {
      intro: "Your 50s reframe what 'optimization' means. The smart protocols pull back from growth signaling and emphasize system maintenance.",
      points: [
        "GH secretion is roughly 30% of peak. Aggressive restoration past physiological range raises cancer-screening stakes.",
        "Total testosterone often dips into the 350–500 ng/dL range, the band where libido and energy complaints surface even without low-T diagnosis.",
        "Sleep architecture changes mean overnight tissue repair shrinks — recovery becomes a daytime priority, not just an overnight one.",
      ],
    },
    bodySections: [
      {
        id: "screening-first",
        eyebrow: "Screening priority",
        title: "Cancer screening before any GH-axis compound",
        paragraphs: [
          "Growth hormone modulators amplify whatever cellular growth signals are already present. Unscreened malignancies — particularly prostate, colon, and skin — change a low-risk compound into a high-risk one. Annual full physical with age-appropriate imaging is the prerequisite, not an afterthought.",
        ],
        bullets: [
          "PSA + DRE within the last 12 months — anything trending up disqualifies aggressive GH-axis stacking until worked up.",
          "Colonoscopy on the age-appropriate schedule.",
          "Full-body skin screen by a dermatologist — Melanotan and pigmentation-affecting compounds are off the menu without it.",
          "Resting ECG and recent lipid panel including ApoB.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "Indications that earn a protocol in your 50s",
        paragraphs: [
          "In your 50s, peptides earn their place when they map to a documented physiological gap — measured low testosterone, demonstrably poor sleep, documented soft-tissue dysfunction, or visceral adiposity that diet alone is not moving. They do not earn a place as anti-aging insurance. Anchor every compound to a number or symptom that you can re-measure.",
        ],
        bullets: [
          "Low free T with symptoms confirmed across two morning draws — treat with a clinician-supervised plan; peptides ride alongside, not in place of TRT.",
          "Joint and tendon dysfunction limiting strength training — BPC-157 has the cleanest case here.",
          "Visceral adiposity with poor metabolic markers — GLP-1s are usually clinician-led at this age, not solo experiments.",
          "Documented overnight recovery failure (poor deep sleep, low HRV) where lifestyle inputs are already optimized.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Conservative dosing as the recovery margin shrinks",
        paragraphs: [
          "The 50s rule is dose low, cycle shorter, screen harder. The same compound that was forgiving at 35 can produce side effects at 55 that take months to resolve. Quarterly labs and quarterly clinician check-ins are baseline. Solo open-ended use is the single largest mistake at this age.",
        ],
        bullets: [
          "Repeat full labs every 3 months during any active protocol — including PSA on GH-axis cycles.",
          "Coordinate every compound with primary care; specifically flag interactions with statins, BP meds, blood thinners, and TRT.",
          "GH secretagogue blocks: 8 weeks on, 4 weeks off, single compound only.",
          "If using a GLP-1, maintain or increase resistance training and protein intake — lean mass loss is harder to rebuild at 55 than at 35.",
        ],
      },
      {
        id: "bridge-to-60s",
        eyebrow: "What changes next",
        title: "How the protocol changes when you turn 60",
        paragraphs: [
          "Past 60, the logic of peptide use flips from intervention to maintenance. Compounds that push growth signaling move further off the menu and compounds that preserve immune function, mobility, and cognition move to the front. The screening cadence tightens and the protocols simplify.",
        ],
        bullets: [
          "Thymic and immune-support compounds become more central; aggressive GH-axis stacking moves off the menu.",
          "Mobility, balance, and bone density become standing priorities — protocols are judged by what they preserve, not what they add.",
          "Every compound coordinated with a clinician aware of your full medication list.",
          "Read on once you cross 60:",
        ],
      },
    ],
    faqs: [
      {
        question: "Is it too late to start peptides at 55?",
        answer: "No. Many of the recovery and longevity compounds have their best risk-reward in this window — the signal is loud, the upside is real, and the protocols are well-defined. The prerequisite is current screening, not a younger biological age.",
      },
      {
        question: "Will GH peptides reverse gray hair or wrinkles?",
        answer: "GH-axis compounds may improve skin elasticity and dermal thickness modestly over a 12-week cycle. They will not reverse hair pigment loss. For skin specifically, GHK-Cu has a more direct mechanism and is often used topically.",
      },
      {
        question: "Can I run TRT and peptides at the same time?",
        answer: "Yes, and many clinicians do. TRT addresses the testosterone axis; peptides address GH, soft tissue, and other systems independently. Coordinate with your prescriber so labs and dosing don't collide.",
      },
    ],
    siblings: [
      { slug: "men-over-40", title: "Peptides for Men Over 40", audience: "Men 40–49" },
      { slug: "men-over-60", title: "Peptides for Men Over 60", audience: "Men 60+" },
      { slug: "low-testosterone", title: "Peptides for Low Testosterone", audience: "Men with low T" },
      { slug: "veterans", title: "Peptides for Veterans", audience: "Veterans" },
    ],
    relatedGoalIds: ["anti_aging", "sexual_health", "recovery"],
  },

  {
    id: "men-over-60",
    slug: "men-over-60",
    cluster: "age-gender",
    audience: "Men 60+",
    audienceChips: ["Male", "60+", "Longevity priority"],
    ageRange: "65+",
    sex: "male",
    seoTitle: "Peptides for Men Over 60 (2026)",
    seoDescription:
      "Three compounds for men 60+: thymic support for immunity, longevity signaling, and joint recovery. Conservative, screened, and matched to the decade.",
    h1: "Peptides for Men Over 60",
    canonicalPath: "/blog/peptides-for/men-over-60",
    primaryKeyword: "peptides for men over 60",
    heroEyebrow: "Demographic guide · Men 60+",
    heroSummary:
      "Longevity is the through-line. Three compounds — thymic, longevity, recovery — focus on system maintenance over growth signaling, with the safety screening to match.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Men 60+ benefit most from compounds that maintain rather than push. Thymic support compounds for immune resilience, longevity-leaning recovery peptides, and joint maintenance with BPC-157 form a conservative three-front protocol.",
    safetyFlags: [
      {
        label: "Comprehensive screening is mandatory",
        detail: "Active malignancy, uncontrolled cardiac disease, and recent major surgery all change the protocol.",
        severity: "danger",
      },
    ],
    priorityGoals: [
      { goalId: "anti_aging", framing: "Past 60, every compound is judged by what it protects, not what it adds." },
      { goalId: "immune", framing: "Thymic involution accelerates after 60 — immune resilience becomes the dominant longevity lever." },
      { goalId: "recovery", framing: "Joint and tendon repair slow further; maintaining mobility is the highest-leverage health intervention." },
    ],
    whyDifferent: {
      intro: "After 60, the protocol logic flips: less growth, more maintenance. Compounds with the cleanest safety profile and the longest human track record come forward.",
      points: [
        "Thymic mass continues to decline, reducing naive T-cell output and increasing infection-related mortality.",
        "Sarcopenia accelerates without resistance training and adequate protein — the recovery margin shrinks fast.",
        "Cellular senescence and inflammaging dominate disease risk; compounds that modulate these pathways have growing evidence.",
      ],
    },
    bodySections: [
      {
        id: "what-to-avoid",
        eyebrow: "Skip list",
        title: "What men over 60 should avoid",
        paragraphs: [
          "Aggressive GH-axis stacking, anything that raises IGF-1 supraphysiologically, and compounds without published long-term safety data move out of the recommended set at this age.",
        ],
        bullets: [
          "MK-677 — IGF-1 elevation without a clear cancer-screening protocol",
          "IGF-1 LR3 — growth signaling that amplifies any undiagnosed neoplasm",
          "Melanotan II — pigmentation changes mask melanoma screening",
          "High-dose CJC-1295 DAC stacks — unnecessary GH push at this age",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "The cases that justify a protocol past 60",
        paragraphs: [
          "Past 60, peptide use is judged by what it preserves rather than what it adds. The compounds that earn a place are the ones with the longest human safety record and the clearest mechanism for maintaining immune function, joint integrity, and recovery from minor injury and illness. Every other reason is weaker than it sounds.",
        ],
        bullets: [
          "Documented thymic involution markers (low naive T-cell counts, recurrent infections) — thymic-support compounds have the cleanest case here.",
          "Joint or tendon issues limiting daily mobility or training — BPC-157 has the strongest safety-and-evidence profile.",
          "Slow recovery from minor surgery, illness, or training stress — short BPC-157 or GHK-Cu courses are reasonable.",
          "Mild cognitive complaints with normal screening labs — discuss with your physician before any compound; do not self-treat memory or focus concerns.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Protocol discipline in the maintenance decade",
        paragraphs: [
          "Conservative dosing, full screening, and ongoing clinical coordination are not optional past 60. The compounds with the longest track records have the cleanest fit; the novel ones with thin human data do not. Every cycle should have a written stop criterion and a screening cadence built in.",
        ],
        bullets: [
          "Full physical, age-appropriate cancer screening, lipid panel, fasting glucose, and PSA current within 12 months — refresh before every new cycle.",
          "Single compound at a time; avoid stacking unless coordinated with a clinician familiar with both compounds.",
          "Disclose every research peptide to your primary care physician and any prescribing specialist — interactions with anticoagulants, BP medications, and diabetes care matter.",
          "Track function, not just labs: gait speed, hand-grip strength, sleep duration, recovery from a typical day's exertion. Functional decline trumps lab improvement.",
        ],
      },
      {
        id: "clinician-conversation",
        eyebrow: "What to raise at each visit",
        title: "The standing topics for every clinician check-in",
        paragraphs: [
          "Past 60, the relationship with primary care becomes the foundation of any safe peptide protocol. The same compound is safe in the context of full clinical coordination and risky without it. Use each visit to confirm the protocol still fits the current medication list, screening status, and recent labs.",
        ],
        bullets: [
          "Every active and recently-stopped peptide, with start dates, doses, and duration.",
          "Any new symptoms — fatigue, joint pain, urinary changes, skin changes, mood shifts — to rule out interaction or unmasked pathology.",
          "Updated medication and supplement list, including OTC anti-inflammatories.",
          "Any change in cancer screening status, cardiovascular workup, or sleep complaints.",
        ],
      },
    ],
    faqs: [
      {
        question: "Are peptides safe at 65 or 70?",
        answer: "The conservative subset — BPC-157, thymic peptides, GHK-Cu, epitalon — has a strong safety record and is widely used in this age group. The compounds to avoid are aggressive GH-axis stackers and anything that pushes IGF-1 above the age-appropriate range.",
      },
      {
        question: "Will peptides extend my life?",
        answer: "Lifespan claims for any single compound are unproven in humans. Many of the longevity-leaning peptides have plausible mechanisms (immune restoration, mitochondrial support, senescence modulation), but the honest framing is healthspan support — preserving function — rather than extension.",
      },
      {
        question: "How do peptides interact with statins and blood pressure meds?",
        answer: "Most research peptides have no documented interaction with statins, ACE inhibitors, or ARBs. Caution applies to GLP-1s combined with blood pressure medication (additive blood pressure drop) and any compound combined with anticoagulants. Coordinate with your prescribing clinician.",
      },
    ],
    siblings: [
      { slug: "men-over-50", title: "Peptides for Men Over 50", audience: "Men 50–59" },
      { slug: "veterans", title: "Peptides for Veterans", audience: "Veterans" },
      { slug: "biohackers", title: "Peptides for Biohackers", audience: "Biohackers" },
    ],
    relatedGoalIds: ["anti_aging", "immune", "recovery"],
  },

  {
    id: "women-in-their-20s",
    slug: "women-in-their-20s",
    cluster: "age-gender",
    audience: "Women 20–29",
    audienceChips: ["Female", "20–29", "Peak baseline"],
    ageRange: "25-34",
    sex: "female",
    seoTitle: "Peptides for Women in Their 20s (2026)",
    seoDescription:
      "Most peptides marketed to women in their 20s are unnecessary. Two compounds — skin and mood — cover the actual evidence-backed cases for this decade.",
    h1: "Peptides for Women in Their 20s",
    canonicalPath: "/blog/peptides-for/women-in-their-20s",
    primaryKeyword: "peptides for women in their 20s",
    heroEyebrow: "Demographic guide · Women 20–29",
    heroSummary:
      "Skin quality and acute mood support are the two real cases for women in their 20s. The rest is marketing.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 7,
    tldr: "Women 20–29 have peak collagen synthesis, full ovarian reserve, and a fully developed HPA axis. The targeted cases for peptides at this age are localized skin repair and short-course mood and anxiety support. Most other compounds are premature.",
    safetyFlags: [
      {
        label: "Never use peptides while pregnant or trying to conceive",
        detail: "Most research peptides lack pregnancy safety data and are contraindicated during conception attempts.",
        severity: "danger",
      },
      {
        label: "Interactions with hormonal birth control",
        detail: "Some peptides may affect liver enzymes that metabolize hormonal contraceptives — disclose to your prescriber.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "skin_hair", framing: "Skin repair and pigmentation are the most evidence-backed cosmetic use cases at any age, and GHK-Cu has the cleanest record." },
      { goalId: "anxiety", framing: "Selank and related compounds have human anxiolytic data without the dependence profile of benzodiazepines." },
    ],
    whyDifferent: {
      intro: "Most of the female-targeted peptide marketing assumes a 45-year-old hormonal profile. At 25, that protocol is solving a problem you don't have.",
      points: [
        "Collagen synthesis is near peak through your 20s — topical GHK-Cu is plausible for repair, but systemic anti-aging stacks are early.",
        "Estradiol and progesterone cycle normally; supplementing the GH or fertility axis without a clinical reason is unwarranted.",
        "Mental health support is the more common acute case — Selank has anxiolytic evidence without the dependence profile of benzodiazepines.",
      ],
    },
    bodySections: [
      {
        id: "what-to-skip",
        eyebrow: "Skip list",
        title: "Peptides being marketed to you that you don't need yet",
        paragraphs: [
          "Anti-aging stacks, GLP-1s for cosmetic weight loss, and GH-axis compounds for body composition all carry meaningful risk for a 24-year-old with a normal hormonal profile. The cost-benefit gets favorable later.",
        ],
        bullets: [
          "Epitalon, NAD+ — anti-aging signaling that hasn't started failing",
          "Semaglutide, tirzepatide for cosmetic weight loss — high muscle loss risk in active 20s women",
          "Melanotan II for tanning — pigmentation changes complicate skin cancer screening",
          "PT-141 — reserved for documented libido or arousal issues",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "The narrow cases that justify a protocol in your 20s",
        paragraphs: [
          "Most peptide marketing aimed at women in their 20s assumes a 45-year-old hormonal profile. At 25, that protocol is solving for a problem you do not have. The two situations that genuinely earn a compound are localized skin or hair repair, and acute mood support — both with conservative protocols and pregnancy-status awareness.",
        ],
        bullets: [
          "Documented skin or scalp issue (acne scarring, post-procedure recovery, telogen effluvium) — topical GHK-Cu has the cleanest case and the lowest systemic exposure.",
          "Persistent anxiety unresponsive to baseline lifestyle work, where benzodiazepine dependence risk is a concern — Selank has human anxiolytic data without the same profile.",
          "Specific soft-tissue injury (post-surgery, recurring tendinopathy) — BPC-157 with a written stop criterion.",
          "Not pregnant, not trying to conceive, not breastfeeding. If any of those apply, almost every research peptide is off the menu.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Cycle-aware protocol discipline",
        paragraphs: [
          "The dominant rule in your 20s is: confirm cycle and pregnancy status before every compound, prefer topical and local-acting over systemic, and run short courses with a clear stop date. The compounds that pass these filters are few, which is the point.",
        ],
        bullets: [
          "Confirm pregnancy status before each cycle if there is any chance — pregnancy and conception attempts contraindicate almost every research peptide.",
          "Disclose every compound to your prescriber, especially around hormonal contraception interactions.",
          "Track your menstrual cycle alongside any protocol — note any pattern change as a hold-and-reassess trigger.",
          "Prefer topical or local-acting compounds (e.g. topical GHK-Cu) over systemic where the indication is local.",
        ],
      },
      {
        id: "bridge-to-30s",
        eyebrow: "What changes next",
        title: "How the calculus shifts when you turn 30",
        paragraphs: [
          "Your 30s are when the protocol logic shifts from \"unnecessary unless specific\" to \"a small set has real value.\" Collagen production drops, metabolic flexibility narrows, and post-pregnancy recovery becomes a common entry point. The cycle-awareness and pregnancy-status filters stay; the indication list grows.",
        ],
        bullets: [
          "Collagen synthesis decline (~1% per year) makes skin protocols more justifiable past 28.",
          "Postpartum recovery, mild metabolic shifts, and recovery margin narrowing all become valid entry points.",
          "Mental-health peptides keep their case; expect anxiety and sleep complaints to surface more under load.",
          "Read on once you cross 30:",
        ],
      },
    ],
    faqs: [
      {
        question: "Is BPC-157 safe for women in their 20s?",
        answer: "BPC-157 has not been studied in pregnancy and is contraindicated during conception attempts or while breastfeeding. For non-pregnant, non-breastfeeding women, the safety profile is comparable to that in men.",
      },
      {
        question: "Will peptides affect my menstrual cycle?",
        answer: "Most research peptides do not interact with the HPG axis directly. The exceptions are kisspeptin (designed to stimulate gonadotropin release), oxytocin (cycle-phase sensitive), and GH-axis compounds in some users. Track your cycle when starting any new compound.",
      },
      {
        question: "Can I use peptides on hormonal birth control?",
        answer: "Most peptides have no documented interaction with combined oral contraceptives or IUDs. Compounds that affect liver enzymes (rare for peptides) could theoretically reduce contraceptive efficacy — disclose all compounds to your prescriber.",
      },
    ],
    siblings: [
      { slug: "women-in-their-30s", title: "Peptides for Women in Their 30s", audience: "Women 30–39" },
      { slug: "women-over-40", title: "Peptides for Women Over 40", audience: "Women 40–49" },
      { slug: "pcos", title: "Peptides for PCOS", audience: "Women with PCOS" },
      { slug: "postpartum", title: "Peptides Postpartum", audience: "Postpartum women" },
    ],
    relatedGoalIds: ["skin_hair", "anxiety"],
  },

  {
    id: "women-in-their-30s",
    slug: "women-in-their-30s",
    cluster: "age-gender",
    audience: "Women 30–39",
    audienceChips: ["Female", "30–39", "Early shift"],
    ageRange: "35-44",
    sex: "female",
    seoTitle: "Peptides for Women in Their 30s (2026)",
    seoDescription:
      "Three compounds for women 30–39: skin support, evidence-backed fat loss, and recovery — matched to the decade where post-pregnancy and early hormonal shifts begin.",
    h1: "Peptides for Women in Their 30s",
    canonicalPath: "/blog/peptides-for/women-in-their-30s",
    primaryKeyword: "peptides for women in their 30s",
    heroEyebrow: "Demographic guide · Women 30–39",
    heroSummary:
      "The decade where collagen, metabolic flexibility, and recovery all begin shifting at once. Three compounds — skin, fat, recovery — cover the real cases without overshooting.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Women 30–39 see collagen production decline ~1% per year, metabolic flexibility narrow, and recovery slow. GHK-Cu for skin, a GLP-1 for fat loss where indicated, and BPC-157 for recovery is the conservative three-front protocol.",
    safetyFlags: [
      {
        label: "Pregnancy, conception, breastfeeding contraindicate most peptides",
        detail: "If you are pregnant, trying to conceive, or breastfeeding, the default answer for almost every research peptide is no.",
        severity: "danger",
      },
    ],
    priorityGoals: [
      { goalId: "skin_hair", framing: "Collagen production drops ~1% per year starting in your late 20s; topical and systemic skin compounds have their strongest case here." },
      { goalId: "fat_loss", framing: "Metabolic flexibility narrows in your 30s — GLP-1s have the cleanest human evidence for stubborn fat in this window." },
      { goalId: "recovery", framing: "Postpartum, post-injury, or simply post-30 — soft tissue recovery margin shrinks measurably." },
    ],
    whyDifferent: {
      intro: "Your 30s are when the maintenance bill comes due — collagen, metabolism, and recovery all start needing deliberate inputs.",
      points: [
        "Skin collagen production declines roughly 1% per year, accelerating after pregnancy.",
        "Metabolic flexibility narrows: glucose tolerance, insulin sensitivity, and visceral fat distribution all shift.",
        "Pelvic floor and abdominal wall recovery from pregnancy can persist as a recovery deficit for years.",
      ],
    },
    bodySections: [
      {
        id: "postpartum-context",
        eyebrow: "Postpartum",
        title: "If you are postpartum",
        paragraphs: [
          "Breastfeeding contraindicates most research peptides. Once you have weaned, BPC-157 and GHK-Cu are the most commonly used recovery and skin compounds, with the longest safety record in non-pregnant women.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "The cases that justify a protocol in your 30s",
        paragraphs: [
          "The 30s are the first decade where peptides have a real case for women outside narrow indications. The mistake is reaching for them as anti-aging insurance. Anchor each compound to a documented shift — a measurable metabolic marker, a skin or recovery issue with a stop criterion, a specific symptom — not a general feeling that something is changing.",
        ],
        bullets: [
          "Stubborn visceral or hip-area fat gain that has resisted 12+ weeks of dialed-in diet and training — a GLP-1 enters the conversation, ideally clinician-led.",
          "Documented postpartum recovery deficit (pelvic floor, abdominal wall, joint laxity) after weaning — BPC-157 has the cleanest case.",
          "Visible skin or collagen changes — topical GHK-Cu has the most direct mechanism with the lowest systemic exposure.",
          "Not pregnant, not breastfeeding, not actively trying to conceive — those statuses move most research peptides off the menu entirely.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline around hormonal context",
        paragraphs: [
          "The defining feature of a 30s women's protocol is cycle and life-stage awareness. The same compound is appropriate at cycle day 5 and questionable on day 25; appropriate before conception attempts and contraindicated during them. Build the protocol around that context, not around it.",
        ],
        bullets: [
          "Confirm pregnancy status before each cycle if there is any chance of conception.",
          "Discontinue GLP-1s at least 2 months before attempting conception — current guidance.",
          "Coordinate with your OB-GYN or primary care, especially around hormonal contraception and any cycle-affecting compound.",
          "Track menstrual cycle changes alongside any protocol — pattern change is a hold-and-reassess trigger.",
        ],
      },
      {
        id: "bridge-to-40s",
        eyebrow: "What changes next",
        title: "How the protocol changes when you turn 40",
        paragraphs: [
          "Your 40s open the perimenopause window. The hormonal flux begins quietly years before symptoms show up, and the compounds that earn space change accordingly. Sleep architecture, body composition, and skin all start moving on the same timeline, driven by the same upstream shifts.",
        ],
        bullets: [
          "Perimenopause symptoms (sleep, mood, fat redistribution, hot flashes) start in the early-to-mid 40s for most women — track them.",
          "GLP-1s remain a primary lever; sleep-supporting peptides earn a more permanent role.",
          "Hormone-replacement therapy decisions begin in this decade — coordinate any peptide protocol around that timeline.",
          "Read on once you cross 40:",
        ],
      },
    ],
    faqs: [
      {
        question: "Can I use peptides while breastfeeding?",
        answer: "No. Almost no research peptide has lactation safety data, and the default answer is to wait until you have weaned. Discuss with your obstetrician if you are considering any compound during the postpartum window.",
      },
      {
        question: "Will peptides reverse stretch marks?",
        answer: "GHK-Cu has the most direct mechanism (collagen and dermal remodeling) and is often used topically for stretch marks. Improvement is modest and gradual — measured in months, not weeks. Combine with microneedling or topical retinoids for best results.",
      },
      {
        question: "Are GLP-1s safe before pregnancy?",
        answer: "Discontinue at least 2 months before attempting conception per current guidance. GLP-1s do not have safety data in pregnancy, and rapid weight loss before conception may not be the desired metabolic starting point.",
      },
    ],
    siblings: [
      { slug: "women-in-their-20s", title: "Peptides for Women in Their 20s", audience: "Women 20–29" },
      { slug: "women-over-40", title: "Peptides for Women Over 40", audience: "Women 40–49" },
      { slug: "postpartum", title: "Peptides Postpartum", audience: "Postpartum women" },
      { slug: "pcos", title: "Peptides for PCOS", audience: "Women with PCOS" },
    ],
    relatedGoalIds: ["skin_hair", "fat_loss", "recovery"],
  },

  {
    id: "women-over-40",
    slug: "women-over-40",
    cluster: "age-gender",
    audience: "Women 40–49",
    audienceChips: ["Female", "40–49", "Perimenopause window"],
    ageRange: "35-44",
    sex: "female",
    seoTitle: "Peptides for Women Over 40 (2026)",
    seoDescription:
      "Three compounds for women 40–49: GLP-1-class fat loss, skin support, and longevity signaling. Matched to the perimenopause-onset decade.",
    h1: "Peptides for Women Over 40",
    canonicalPath: "/blog/peptides-for/women-over-40",
    primaryKeyword: "peptides for women over 40",
    heroEyebrow: "Demographic guide · Women 40–49",
    heroSummary:
      "The decade when fat redistributes, skin thins, and perimenopause begins quietly. Three compounds — fat loss, skin, longevity — match the dominant shifts.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Women 40–49 enter perimenopause with falling estradiol, redistributing fat toward the midsection, and accelerating collagen loss. A GLP-1 for the metabolic shift, GHK-Cu for skin, and a longevity compound for system support form a focused three-front protocol.",
    safetyFlags: [
      {
        label: "Hormone status changes everything",
        detail: "Coordinate with your gynecologist or HRT prescriber — peptide choices interact with estrogen status, cycle, and menopause stage.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "fat_loss", framing: "Estradiol decline shifts fat toward the midsection — GLP-1s show some of their strongest human evidence in this window." },
      { goalId: "skin_hair", framing: "Collagen loss accelerates as estradiol falls; skin elasticity, hair density, and nail strength all need direct support." },
      { goalId: "anti_aging", framing: "The first decade where 'aging' becomes a discrete project — longevity-leaning compounds earn their place." },
    ],
    whyDifferent: {
      intro: "Perimenopause is the defining variable of the 40s for women. Every compound choice is read against the falling-estradiol backdrop.",
      points: [
        "Estradiol begins fluctuating in the late 30s and trends downward through the 40s, driving fat redistribution and collagen loss.",
        "Visceral fat accumulation accelerates regardless of caloric intake, mirroring the male midlife pattern.",
        "Sleep fragmentation and night sweats appear in the late 40s for many women, compounding recovery deficits.",
      ],
    },
    bodySections: [
      {
        id: "perimenopause-link",
        eyebrow: "Coordinate",
        title: "If you suspect perimenopause",
        paragraphs: [
          "Cycle irregularity, sleep disruption, and unexplained mood shifts often precede measurable hormonal changes by years. Track symptoms, get FSH and estradiol panels, and coordinate any peptide protocol with your gynecologist — especially if HRT is on the table.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "Indications that earn a protocol in your 40s",
        paragraphs: [
          "Your 40s are the decade where the case for peptides moves from narrow to broad — but each compound has to be read against the falling-estradiol backdrop. Anchor every decision to a measurable shift (visible body composition, documented sleep failure, perimenopause symptoms, lab marker) and treat compounds as risk-managed levers alongside hormone-replacement decisions rather than substitutes for them.",
        ],
        bullets: [
          "Visceral fat redistribution that has resisted 12+ weeks of dialed-in diet and training — incretin-class compounds enter, clinician-supervised.",
          "Documented sleep failure (poor deep sleep, night sweats, early waking) where lifestyle inputs are dialed — sleep-supporting peptides have a case once HRT options are on the table.",
          "Visible skin or collagen changes — topical GHK-Cu has the cleanest case and the lowest systemic exposure.",
          "Documented soft-tissue recovery deficit limiting training or daily function — BPC-157 has the strongest evidence.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Protocol discipline through perimenopause",
        paragraphs: [
          "The defining rule for women's 40s protocols is HRT-aware sequencing. The same compound interacts differently with cycling hormone levels than with stable HRT levels, and your gynecologist needs to see the full picture. Repeat FSH and estradiol panels alongside metabolic markers each quarter during any active protocol.",
        ],
        bullets: [
          "Repeat full labs every 3 months — fasting glucose, HbA1c, lipid panel including ApoB, FSH, estradiol, free T, IGF-1, thyroid.",
          "If using a GLP-1, maintain resistance training and high protein — bone density loss accelerates in this window without it.",
          "Coordinate every compound with your gynecologist or primary care; flag interactions with hormonal contraception and any future HRT.",
          "Establish a DEXA baseline (bone density and body composition) before age 50 — it sets the floor for the next two decades.",
        ],
      },
      {
        id: "bridge-to-50s",
        eyebrow: "What changes next",
        title: "How the protocol changes when you turn 50",
        paragraphs: [
          "Your 50s are when most women cross into postmenopause. Bone density becomes the dominant longevity input, body composition stops responding to old strategies, and the case for HRT becomes more concrete. Peptide protocols shift to support those priorities rather than chase 30s-style outcomes.",
        ],
        bullets: [
          "Bone density, fracture prevention, and muscle preservation become the structural priorities for the next two decades.",
          "HRT decisions, if made, anchor the rest of the protocol — peptides become layered context, not lead actors.",
          "Cognitive complaints rise into the foreground; sleep-supporting peptides shift from optional to commonly indicated.",
          "Read on once you cross 50:",
        ],
      },
    ],
    faqs: [
      {
        question: "Will GLP-1s affect my cycle or fertility?",
        answer: "GLP-1s can shift cycle regularity transiently, and rapid weight loss itself can affect ovulation. If you are trying to conceive, discontinue at least 2 months before attempting. If contraception is needed, GLP-1s may delay oral contraceptive absorption — consider non-oral methods during initiation.",
      },
      {
        question: "Can I use peptides with HRT?",
        answer: "Yes, and many women do. HRT addresses the estradiol or progesterone deficit; peptides address GH, soft tissue, skin, and metabolic levers independently. Coordinate with your prescriber so labs reflect the combined picture.",
      },
      {
        question: "Is it too early for anti-aging peptides at 42?",
        answer: "No — the longevity-leaning compounds (epitalon, thymic peptides, GHK-Cu) have their best risk-reward when the underlying decline has started but is not yet entrenched. Late 30s and 40s is the standard starting window.",
      },
    ],
    siblings: [
      { slug: "women-in-their-30s", title: "Peptides for Women in Their 30s", audience: "Women 30–39" },
      { slug: "women-over-50", title: "Peptides for Women Over 50", audience: "Women 50–59" },
      { slug: "perimenopause", title: "Peptides for Perimenopause", audience: "Perimenopausal women" },
      { slug: "menopause", title: "Peptides for Menopause", audience: "Menopausal women" },
    ],
    relatedGoalIds: ["fat_loss", "skin_hair", "anti_aging"],
  },

  {
    id: "women-over-50",
    slug: "women-over-50",
    cluster: "age-gender",
    audience: "Women 50–59",
    audienceChips: ["Female", "50–59", "Menopause"],
    ageRange: "45-54",
    sex: "female",
    seoTitle: "Peptides for Women Over 50 (2026)",
    seoDescription:
      "Three compounds for women 50–59: longevity support, skin and collagen, and sleep architecture. Matched to the menopause window.",
    h1: "Peptides for Women Over 50",
    canonicalPath: "/blog/peptides-for/women-over-50",
    primaryKeyword: "peptides for women over 50",
    heroEyebrow: "Demographic guide · Women 50–59",
    heroSummary:
      "Menopause reshapes the protocol. Three compounds — longevity, skin, sleep — address the dominant complaints of the decade.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Post-menopausal women face dramatic estradiol loss, accelerated collagen breakdown, and disrupted sleep architecture. A longevity-leaning compound for system support, GHK-Cu for skin, and DSIP or epitalon for sleep is the conservative three-front protocol.",
    safetyFlags: [
      {
        label: "Coordinate with HRT decisions",
        detail: "HRT remains the dominant variable for menopausal symptoms. Peptide choices should complement, not substitute for, that decision.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "anti_aging", framing: "Estradiol loss accelerates almost every system marker — longevity-leaning compounds with clean safety profiles do the most." },
      { goalId: "skin_hair", framing: "Skin thins measurably in the first 5 years post-menopause; direct collagen support has real evidence here." },
      { goalId: "sleep", framing: "Disrupted sleep is the single most common menopausal complaint and the lever that compounds everything else." },
    ],
    whyDifferent: {
      intro: "The hormonal floor that defined the previous five decades is gone. The protocol logic shifts toward maintenance and sleep.",
      points: [
        "Estradiol drops to roughly 10% of pre-menopausal levels, removing the dominant signal for skin, bone, and cardiovascular health.",
        "Slow-wave sleep declines; menopausal sleep fragmentation amplifies cortisol and worsens visceral fat accumulation.",
        "Bone density loss accelerates in the first 5 years post-menopause — system support compounds matter more here than in any previous decade.",
      ],
    },
    bodySections: [
      {
        id: "sleep-priority",
        eyebrow: "Sleep first",
        title: "Why sleep is the keystone variable",
        paragraphs: [
          "If only one input changes in your 50s, make it sleep. Disrupted sleep drives cortisol, glucose dysregulation, mood symptoms, and visceral fat accumulation simultaneously. DSIP and epitalon have human data for sleep architecture support without the next-day cognitive cost of benzodiazepines.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "Indications that earn a protocol in your 50s",
        paragraphs: [
          "Postmenopause, the protocol logic changes from chasing outcomes to defending function. The compounds that earn a place address sleep, body composition, soft-tissue maintenance, and immune resilience — not anti-aging in the cosmetic sense. Each one rides alongside the larger HRT-versus-no-HRT decision your clinician is already navigating with you.",
        ],
        bullets: [
          "Documented sleep failure (poor deep sleep, night sweats, early waking) that has not resolved with sleep hygiene or HRT alone.",
          "Visceral fat redistribution and resistance to old strategies — GLP-1s have a real case, clinician-led, with bone density and muscle protection built in.",
          "Joint and tendon dysfunction limiting strength training or mobility — BPC-157 supports recovery without estrogen interactions.",
          "Low bone density on DEXA — peptides are not osteoporosis treatment; coordinate with your clinician on the larger pharmacological plan.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline alongside HRT and structural priorities",
        paragraphs: [
          "Your 50s protocol must coexist with the HRT decision and with the bone density and cardiovascular workups your primary care is doing. The same compound that was casual at 35 deserves a clinician sign-off at 55. Single-compound, short-block, and quarterly labs are the defaults.",
        ],
        bullets: [
          "Establish DEXA baseline (bone density and body composition) before starting any GLP-1 protocol.",
          "Repeat labs every 3 months — fasting glucose, HbA1c, lipid panel with ApoB, FSH, estradiol, IGF-1, thyroid, and bone turnover markers if relevant.",
          "If using a GLP-1, maintain or increase resistance training and protein intake — bone and muscle loss in this decade rarely fully reverses.",
          "Coordinate every compound with your HRT prescriber and primary care — interactions matter more in this window than any prior.",
        ],
      },
      {
        id: "bridge-to-60s",
        eyebrow: "What changes next",
        title: "How the protocol changes when you turn 60",
        paragraphs: [
          "Past 60, protocols simplify further. The compounds that earn space are the ones with the longest human safety record and the cleanest mechanism for preserving immune function, bone density, and recovery from minor illness. Aesthetic and aggressive body-composition goals move off the menu; functional preservation moves to the front.",
        ],
        bullets: [
          "Thymic and immune-support compounds become more central; aggressive GH-axis stacking moves off the menu.",
          "Mobility, balance, bone density, and cognitive function become the standing priorities.",
          "Compound coordination with primary care is non-negotiable.",
          "Read on once you cross 60:",
        ],
      },
    ],
    faqs: [
      {
        question: "Can I use peptides if I am on HRT?",
        answer: "Yes. HRT replaces hormones; peptides act on independent pathways (GH, soft tissue, sleep, immune). Many women run them together. Coordinate with your HRT prescriber so labs reflect the combined picture.",
      },
      {
        question: "Will peptides help with hot flashes?",
        answer: "Most research peptides do not directly address vasomotor symptoms. Sleep-supporting compounds (DSIP, epitalon) reduce the secondary impact of night sweats on rest. The first-line treatment for hot flashes themselves remains HRT or specific non-hormonal medications.",
      },
      {
        question: "Should I start a longevity stack now?",
        answer: "Your 50s are the standard starting window for longevity-leaning compounds. Thymic support and senescence-modulating peptides have their best risk-reward when underlying decline has started but is not yet advanced.",
      },
    ],
    siblings: [
      { slug: "women-over-40", title: "Peptides for Women Over 40", audience: "Women 40–49" },
      { slug: "women-over-60", title: "Peptides for Women Over 60", audience: "Women 60+" },
      { slug: "menopause", title: "Peptides for Menopause", audience: "Menopausal women" },
      { slug: "perimenopause", title: "Peptides for Perimenopause", audience: "Perimenopausal women" },
    ],
    relatedGoalIds: ["anti_aging", "skin_hair", "sleep"],
  },

  {
    id: "women-over-60",
    slug: "women-over-60",
    cluster: "age-gender",
    audience: "Women 60+",
    audienceChips: ["Female", "60+", "Longevity priority"],
    ageRange: "65+",
    sex: "female",
    seoTitle: "Peptides for Women Over 60 (2026)",
    seoDescription:
      "Three compounds for women 60+: longevity support, immune resilience, and cognitive maintenance. Conservative, screened, and matched to the decade.",
    h1: "Peptides for Women Over 60",
    canonicalPath: "/blog/peptides-for/women-over-60",
    primaryKeyword: "peptides for women over 60",
    heroEyebrow: "Demographic guide · Women 60+",
    heroSummary:
      "Cognitive and immune maintenance lead the protocol. Three compounds — longevity, immune, cognitive — focus on healthspan rather than performance.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Women 60+ benefit most from compounds that maintain neurocognitive and immune function. A longevity-leaning peptide, thymic immune support, and a cognitive compound form a conservative three-front protocol focused on independent living, not optimization.",
    safetyFlags: [
      {
        label: "Comprehensive screening is mandatory",
        detail: "Annual physical with cancer screening before any growth-related compound. Anticoagulants and antihypertensives need coordination.",
        severity: "danger",
      },
    ],
    priorityGoals: [
      { goalId: "anti_aging", framing: "Healthspan and functional independence are the dominant goals — every compound is judged against those." },
      { goalId: "immune", framing: "Thymic involution and immunosenescence drive infection-related mortality risk post-60." },
      { goalId: "cognitive", framing: "Subtle cognitive shifts in the 60s predict trajectory — neurotrophic support has its best risk-reward early." },
    ],
    whyDifferent: {
      intro: "Past 60, peptide selection is conservative by default. Maintain, screen, and avoid amplifying any growth signal that hasn't been ruled out.",
      points: [
        "Immune senescence increases the cost of every infection — thymic compounds have direct mechanistic support.",
        "Cognitive decline starts subtly in this decade; neurotrophic compounds are most useful before measurable impairment.",
        "Bone density continues falling — coordinate any compound choice with osteoporosis treatment and weight-bearing exercise.",
      ],
    },
    bodySections: [
      {
        id: "screen-then-add",
        eyebrow: "Screen first",
        title: "Screen aggressively before adding compounds",
        paragraphs: [
          "Annual physical with mammography, colonoscopy as indicated, bone density scan, and comprehensive labs is the prerequisite. Any growth-signaling compound amplifies whatever cellular activity is already present.",
        ],
        bullets: [
          "Mammography current within 12 months — any imaging follow-up takes precedence over starting a new compound.",
          "Colonoscopy on the age-appropriate schedule.",
          "Bone density (DEXA) within 24 months — informs whether compounds belong in the protocol at all.",
          "Full-body skin screen by a dermatologist annually.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "Indications that justify a protocol past 60",
        paragraphs: [
          "Past 60, the case for peptides is preservation: immune function, mobility, recovery from minor stress, cognitive sharpness. Aesthetic and aggressive body-composition goals belong to earlier decades. The compounds that earn space have decades of human data and clear mechanisms for preserving function.",
        ],
        bullets: [
          "Recurrent infections or documented immune decline — thymic-support compounds have the cleanest case.",
          "Joint and tendon dysfunction limiting daily mobility — BPC-157 supports recovery with strong safety record.",
          "Mild cognitive complaints with normal screening labs — discuss with your physician before starting any neurotrophic compound.",
          "Slow recovery from minor surgery, illness, or training stress — short BPC-157 or GHK-Cu courses are reasonable.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Maintenance-decade protocol discipline",
        paragraphs: [
          "Conservative dosing, full screening, and ongoing clinical coordination define every protocol past 60. The compounds with the longest track records have the cleanest fit; the novel ones with thin human data do not belong here. Every cycle has a written stop criterion and a screening cadence.",
        ],
        bullets: [
          "Single compound at a time unless coordinated with a clinician familiar with both.",
          "Disclose every research peptide to your primary care, gynecologist, and any prescribing specialist.",
          "Repeat full labs every 3 months during any active protocol.",
          "Track function — gait speed, grip strength, sleep duration, recovery — not just labs. Functional decline trumps lab improvement.",
        ],
      },
      {
        id: "clinician-conversation",
        eyebrow: "What to raise at each visit",
        title: "Standing topics for every clinician check-in",
        paragraphs: [
          "The relationship with primary care becomes the foundation of any safe peptide protocol past 60. Use each visit to confirm the protocol still fits your current medication list, screening status, and recent labs — and to flag any new symptom that could be interaction-related rather than age-related.",
        ],
        bullets: [
          "Every active and recently-stopped peptide, with start dates, doses, and duration.",
          "Any new symptoms — fatigue, joint pain, mood shifts, cognitive changes, urinary changes.",
          "Full medication and supplement list including OTC anti-inflammatories.",
          "Any change in cancer screening status, bone density, cardiovascular workup, or sleep.",
        ],
      },
    ],
    faqs: [
      {
        question: "Are peptides safe at 70 or 75?",
        answer: "The conservative subset — thymic peptides, GHK-Cu, BPC-157, epitalon, cerebrolysin — has a strong safety record into the 70s. The compounds to avoid are aggressive GH-axis stackers and anything that pushes IGF-1 above age-appropriate ranges.",
      },
      {
        question: "Will peptides help with memory complaints?",
        answer: "Neurotrophic compounds (semax, dihexa, cerebrolysin) have human data for mild cognitive concerns. They are not a treatment for diagnosed dementia. If memory complaints are persistent or progressive, a neurology evaluation comes first.",
      },
      {
        question: "Do peptides interact with osteoporosis medications?",
        answer: "Most research peptides have no documented interaction with bisphosphonates, denosumab, or PTH analogs. Coordinate with your prescribing clinician for any combined protocol.",
      },
    ],
    siblings: [
      { slug: "women-over-50", title: "Peptides for Women Over 50", audience: "Women 50–59" },
      { slug: "menopause", title: "Peptides for Menopause", audience: "Menopausal women" },
      { slug: "biohackers", title: "Peptides for Biohackers", audience: "Biohackers" },
    ],
    relatedGoalIds: ["anti_aging", "immune", "cognitive"],
  },

  // ──────────────────────────────────────────────────────────────────
  // LIFE-STAGE
  // ──────────────────────────────────────────────────────────────────
  {
    id: "perimenopause",
    slug: "perimenopause",
    cluster: "life-stage",
    audience: "Perimenopausal women",
    audienceChips: ["Female", "Perimenopause", "Cycle changes"],
    ageRange: "45-54",
    sex: "female",
    seoTitle: "Peptides for Perimenopause (2026)",
    seoDescription:
      "Three compounds for perimenopause: sleep architecture support, evidence-backed fat loss, and anxiety relief. Matched to the hormonal flux window.",
    h1: "Peptides for Perimenopause",
    canonicalPath: "/blog/peptides-for/perimenopause",
    primaryKeyword: "peptides for perimenopause",
    medicalCondition: "Perimenopause",
    heroEyebrow: "Life stage · Perimenopause",
    heroSummary:
      "Perimenopause is the variability decade. Three compounds — sleep, fat, anxiety — address the symptoms that most disrupt daily function.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Perimenopause is defined by erratic estradiol and progesterone, fragmented sleep, sudden weight redistribution, and elevated anxiety. A sleep-supporting peptide, a GLP-1 where indicated, and Selank for acute anxiety form the highest-impact three-front protocol.",
    safetyFlags: [
      {
        label: "Confirm perimenopause with labs",
        detail: "FSH, estradiol, and progesterone panels (and symptom tracking) clarify which interventions apply.",
        severity: "info",
      },
      {
        label: "Coordinate with HRT decisions",
        detail: "HRT remains the dominant lever — peptides complement, they don't replace.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "sleep", framing: "Sleep fragmentation is often the first and most disruptive perimenopausal symptom — fixing it improves everything downstream." },
      { goalId: "fat_loss", framing: "Sudden midsection weight gain despite stable habits is the hallmark metabolic shift of perimenopause." },
      { goalId: "anxiety", framing: "Anxiety and mood lability track hormonal flux directly — short-course anxiolytic peptides reduce the acute burden." },
    ],
    whyDifferent: {
      intro: "Perimenopause is not menopause. The defining feature is unpredictability — hormones cycle, surge, and crash without a clean trajectory.",
      points: [
        "Estradiol fluctuates wildly before declining, producing variable symptom intensity that confounds standard treatment timing.",
        "Progesterone often falls first, contributing to anxiety, sleep disruption, and shortened cycles.",
        "Cortisol rises in response to fragmented sleep and mood shifts, accelerating visceral fat accumulation in a feedback loop.",
      ],
    },
    bodySections: [
      {
        id: "track-symptoms",
        eyebrow: "Tracking",
        title: "Symptom tracking changes the protocol",
        paragraphs: [
          "Perimenopause is best managed with data, not impressions. Track cycle length, sleep quality, hot flash frequency, and mood symptoms for 90 days before adding compounds. The pattern often clarifies which lever to pull first.",
        ],
        bullets: [
          "Cycle length and irregularity — shortening cycles often precede other symptoms by 6–12 months.",
          "Sleep quality: time to fall asleep, number of awakenings, total sleep time.",
          "Hot flash frequency and intensity by time of day.",
          "Mood and anxiety severity, ideally on the same simple scale daily.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "Indications that justify a peptide alongside HRT",
        paragraphs: [
          "Perimenopause protocols are built around HRT — the dominant lever for the dominant problem (declining and erratic estradiol and progesterone). Peptides earn a place where HRT alone has not closed the gap on a specific symptom, or where a measurable metabolic shift demands its own intervention.",
        ],
        bullets: [
          "Sleep failure persisting through HRT initiation or in women not pursuing HRT — DSIP and related sleep-supporting compounds have a case.",
          "Midsection weight gain unresponsive to dialed-in diet and training over 12+ weeks — incretin-class compounds, clinician-supervised.",
          "Acute anxiety not controlled by lifestyle, where benzodiazepine dependence is a concern — Selank has the cleanest case.",
          "Recurring soft-tissue issues — BPC-157 supports recovery without estrogen interactions.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Protocol discipline through hormonal flux",
        paragraphs: [
          "The defining rule for perimenopause protocols is HRT-first sequencing. Add peptides only after HRT decisions are stable and you have 8–12 weeks of symptom data on the HRT regimen. Repeat FSH and estradiol quarterly during any active protocol.",
        ],
        bullets: [
          "Coordinate every compound with your gynecologist; flag interactions with HRT, hormonal contraception, and any antidepressant.",
          "Repeat full labs every 3 months — FSH, estradiol, progesterone, lipid panel with ApoB, fasting glucose, HbA1c, thyroid.",
          "Track cycle alongside any protocol — pattern change is a hold-and-reassess trigger.",
          "Bone density (DEXA) baseline before age 50.",
        ],
      },
      {
        id: "bridge-to-menopause",
        eyebrow: "What changes next",
        title: "How the protocol changes when periods stop",
        paragraphs: [
          "Postmenopause (12 months without a period) brings stability — but at a lower hormonal baseline. The compounds that earned their place during perimenopause keep their case; new priorities (bone density, cardiovascular, cognitive) move into the foreground. HRT decisions become longer-arc, and peptide protocols simplify alongside.",
        ],
        bullets: [
          "Symptom variability decreases — protocols stabilize after the flux period ends.",
          "Bone density loss accelerates in the first 5 years postmenopause — fortify the structural priorities.",
          "Cardiovascular risk profile shifts — ApoB and metabolic markers earn quarterly attention.",
          "Read on once perimenopause ends:",
        ],
      },
    ],
    faqs: [
      {
        question: "How do I know if I am in perimenopause?",
        answer: "Cycle changes (shortening, irregularity, skipped periods), sleep disruption, hot flashes, mood lability, and new-onset anxiety are the classic markers. FSH > 25 with low or variable estradiol confirms it, but labs are unreliable mid-cycle.",
      },
      {
        question: "Will peptides delay menopause?",
        answer: "No research peptide is known to delay the menopausal transition. Some compounds may improve perimenopausal symptoms (sleep, mood, weight) without altering the underlying hormonal trajectory.",
      },
      {
        question: "Can I run a GLP-1 if I still have a regular cycle?",
        answer: "Yes, with the standard caveats — discontinue 2 months before any conception attempt, and use non-oral contraception during initiation if pregnancy prevention matters.",
      },
    ],
    siblings: [
      { slug: "menopause", title: "Peptides for Menopause", audience: "Menopausal women" },
      { slug: "women-over-40", title: "Peptides for Women Over 40", audience: "Women 40–49" },
      { slug: "women-over-50", title: "Peptides for Women Over 50", audience: "Women 50–59" },
      { slug: "pcos", title: "Peptides for PCOS", audience: "Women with PCOS" },
    ],
    relatedGoalIds: ["sleep", "fat_loss", "anxiety"],
  },

  {
    id: "menopause",
    slug: "menopause",
    cluster: "life-stage",
    audience: "Menopausal women",
    audienceChips: ["Female", "Post-menopause", "Hormonal floor"],
    ageRange: "55-64",
    sex: "female",
    seoTitle: "Peptides for Menopause (2026)",
    seoDescription:
      "Three compounds for post-menopausal women: longevity support, sleep architecture, and skin and collagen. Matched to the post-transition window.",
    h1: "Peptides for Menopause",
    canonicalPath: "/blog/peptides-for/menopause",
    primaryKeyword: "peptides for menopause",
    medicalCondition: "Menopause",
    heroEyebrow: "Life stage · Menopause",
    heroSummary:
      "Post-transition, the protocol stabilizes. Three compounds — longevity, sleep, skin — address the persistent costs of the new hormonal floor.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Post-menopausal women face permanent low estradiol, accelerated bone loss, persistent sleep changes, and visible skin thinning. A longevity-leaning peptide, DSIP or epitalon for sleep, and GHK-Cu for skin form the standard three-front maintenance protocol.",
    safetyFlags: [
      {
        label: "Bone density screening is the priority",
        detail: "DEXA scan within 5 years of menopause is standard — bone loss accelerates fastest in this window.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "anti_aging", framing: "The hormonal floor that protected multiple systems is gone — longevity-leaning compounds become more relevant, not less." },
      { goalId: "sleep", framing: "Slow-wave sleep declines persistently after menopause; restoration is high-leverage." },
      { goalId: "skin_hair", framing: "Skin thickness drops measurably in the first 5 years post-menopause — direct collagen support has its best risk-reward here." },
    ],
    whyDifferent: {
      intro: "Menopause is a new physiological baseline, not a temporary state. The protocol logic shifts to maintenance of what remains.",
      points: [
        "Estradiol settles at roughly 10% of pre-menopausal levels and stays there — every system calibrated to higher estradiol must adapt.",
        "Bone density loss accelerates for the first 5 years, then slows — this is the highest-leverage window for intervention.",
        "Cognitive complaints in early menopause often resolve, but vasomotor symptoms (hot flashes) can persist for over a decade.",
      ],
    },
    bodySections: [
      {
        id: "hrt-context",
        eyebrow: "HRT context",
        title: "Where peptides fit alongside HRT",
        paragraphs: [
          "HRT remains the strongest intervention for menopausal symptoms and long-term bone, cardiovascular, and cognitive outcomes when started in the right window. Peptides complement HRT by addressing soft tissue, sleep architecture, immune function, and longevity signaling — pathways that estrogen alone does not cover.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "Indications that earn a protocol postmenopause",
        paragraphs: [
          "Postmenopause is a permanent physiological baseline, not a passing phase. The compounds that earn space address what HRT alone does not: soft tissue, sleep architecture, immune function, and skin and collagen. Each one rides alongside whatever HRT plan your clinician has built — they are layered on, not substituted for.",
        ],
        bullets: [
          "Sleep failure persisting through HRT — DSIP and related compounds support architecture without next-day cost.",
          "Body composition resistance (visceral fat, lean mass loss) — GLP-1s with bone and muscle protection, clinician-led.",
          "Visible skin or collagen changes — topical GHK-Cu has the cleanest case.",
          "Joint and tendon dysfunction limiting function — BPC-157 supports recovery independent of estrogen status.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Protocol discipline at a new physiological baseline",
        paragraphs: [
          "Postmenopausal protocols must coexist with HRT decisions, bone-density work, and the cardiovascular workup your primary care is already running. Quarterly labs and ongoing clinician coordination are standard. Single-compound, short-block, and DEXA-baselined are the defaults.",
        ],
        bullets: [
          "Establish DEXA baseline before starting any GLP-1; recheck every 12 months on protocol.",
          "Coordinate every compound with your HRT prescriber and primary care.",
          "Repeat full labs every 3 months — fasting glucose, HbA1c, ApoB-inclusive lipid panel, IGF-1, thyroid, FSH/estradiol if on HRT.",
          "Maintain resistance training and high protein intake — bone and muscle loss accelerates without them.",
        ],
      },
      {
        id: "bridge-to-postmenopausal-stability",
        eyebrow: "What changes next",
        title: "The decade after menopause stabilizes",
        paragraphs: [
          "The first five years postmenopause are the high-leverage window for structural intervention — bone density, cardiovascular profile, body composition all respond best to action in this period. After that, protocols simplify and the priorities shift toward maintenance and screening cadence.",
        ],
        bullets: [
          "Bone density loss decelerates after the first 5 years — the early window is where intervention pays the most.",
          "Cardiovascular and metabolic priorities become standing quarterly metrics, not annual.",
          "Aesthetic and aggressive body-composition goals give way to function preservation.",
          "Read on once you cross 60:",
        ],
      },
    ],
    faqs: [
      {
        question: "Should I take peptides instead of HRT?",
        answer: "No. HRT is the dominant intervention for menopausal symptoms and long-term outcomes for most women. Peptides address complementary pathways. Discuss HRT with a menopause-trained clinician first; layer peptides as a secondary support, not a replacement.",
      },
      {
        question: "Will peptides help with hot flashes specifically?",
        answer: "Most research peptides do not directly affect vasomotor symptoms. Sleep-supporting peptides (DSIP, epitalon) reduce the secondary impact of night sweats on rest. For hot flashes themselves, HRT or specific non-hormonal medications are first-line.",
      },
      {
        question: "How long should I stay on a longevity peptide?",
        answer: "Most longevity-leaning compounds (epitalon, thymic peptides) are run in cycles — typically 10–20 days of injection followed by 3–6 months off, repeated annually. Continuous use is not the standard protocol.",
      },
    ],
    siblings: [
      { slug: "perimenopause", title: "Peptides for Perimenopause", audience: "Perimenopausal women" },
      { slug: "women-over-50", title: "Peptides for Women Over 50", audience: "Women 50–59" },
      { slug: "women-over-60", title: "Peptides for Women Over 60", audience: "Women 60+" },
    ],
    relatedGoalIds: ["anti_aging", "sleep", "skin_hair"],
  },

  {
    id: "postpartum",
    slug: "postpartum",
    cluster: "life-stage",
    audience: "Postpartum women",
    audienceChips: ["Female", "Postpartum", "Recovery"],
    ageRange: "25-34",
    sex: "female",
    seoTitle: "Peptides Postpartum (2026)",
    seoDescription:
      "Three compounds for postpartum recovery: tissue repair, skin and stretch mark support, and anxiety relief. Breastfeeding-aware guidance.",
    h1: "Peptides Postpartum",
    canonicalPath: "/blog/peptides-for/postpartum",
    primaryKeyword: "peptides postpartum",
    medicalCondition: "Postpartum Period",
    heroEyebrow: "Life stage · Postpartum",
    heroSummary:
      "After breastfeeding, three compounds address the persistent recovery deficits — soft tissue, skin, and anxiety — that pregnancy and childbirth leave behind.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Postpartum recovery includes abdominal wall healing, pelvic floor recovery, skin remodeling, and mood normalization. After breastfeeding ends, BPC-157 for tissue repair, GHK-Cu for skin, and Selank for mood support form a focused recovery protocol.",
    safetyFlags: [
      {
        label: "Do not use while breastfeeding",
        detail: "Almost no research peptide has lactation safety data. Wait until you have weaned before starting any compound.",
        severity: "danger",
      },
      {
        label: "Six-week postpartum clearance first",
        detail: "Standard postpartum clinical clearance before any new intervention, including peptides.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "recovery", framing: "Abdominal wall and pelvic floor recovery can persist as a deficit for years — direct tissue support has a real case." },
      { goalId: "skin_hair", framing: "Stretch marks, hair shedding, and skin laxity are the most common postpartum cosmetic complaints — GHK-Cu has the cleanest mechanism." },
      { goalId: "anxiety", framing: "Postpartum anxiety is separate from postpartum depression and often underdiagnosed — short-course anxiolytic compounds may help once cleared by your clinician." },
    ],
    whyDifferent: {
      intro: "Postpartum is not a return to baseline. It is a distinct recovery phase with biological costs that often persist long after the six-week checkup.",
      points: [
        "Abdominal wall diastasis affects a large fraction of postpartum women and can persist without targeted rehab.",
        "Hair shedding (telogen effluvium) peaks around 3–4 months postpartum and is hormonally driven.",
        "Sleep disruption and HPA axis dysregulation can persist for 12+ months, compounding everything else.",
      ],
    },
    bodySections: [
      {
        id: "breastfeeding-first",
        eyebrow: "Breastfeeding",
        title: "If you are still breastfeeding, wait",
        paragraphs: [
          "Lactation safety data does not exist for most research peptides. The conservative answer is to wait until you have weaned before starting any compound. If a specific clinical issue cannot wait, discuss with your obstetrician — never self-prescribe during breastfeeding.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When it actually makes sense",
        title: "Indications that justify a protocol once weaned",
        paragraphs: [
          "Postpartum is a distinct recovery phase, not a return to baseline. Once weaned and cleared, peptides earn space when sleep, body composition, soft-tissue recovery, or skin and hair changes have not resolved with time and lifestyle alone. Anchor each compound to a specific symptom with a measurable endpoint.",
        ],
        bullets: [
          "Documented abdominal wall or pelvic floor dysfunction that has not responded to 12+ weeks of targeted rehab — BPC-157 has the cleanest case.",
          "Stubborn postpartum weight that has resisted 12+ weeks of dialed-in inputs — GLP-1s only after 2+ months weaned and clinician-led.",
          "Telogen effluvium past month 9 — topical GHK-Cu has a direct mechanism for follicle environment.",
          "Persistent anxiety that primary care or perinatal specialist has assessed and where peptide-class adjuncts are appropriate.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline through a recovery window",
        paragraphs: [
          "Postpartum protocols are short, conservative, and built around full clinical clearance. The dominant rule: confirm you are weaned, cleared, and not planning another pregnancy in the protocol window. The same compounds you would consider at any other time become contraindicated again the moment a new pregnancy is on the table.",
        ],
        bullets: [
          "Confirm full weaning and six-week clearance before any peptide.",
          "Coordinate with obstetric or perinatal care, especially around postpartum mental health.",
          "Restart any GLP-1 only after 2+ months weaned; discontinue 2+ months before any future conception attempt.",
          "Sleep, protein, training volume — the foundational inputs come back first. Peptides ride on top of them, not in place.",
        ],
      },
      {
        id: "bridge-to-next-cycle",
        eyebrow: "What changes next",
        title: "When postpartum becomes the new normal",
        paragraphs: [
          "Most acute postpartum changes resolve by 12–18 months. The protocol that fits the recovery window is not the protocol that fits the year that follows. As cycle, sleep, and recovery markers stabilize, the relevant guide is the broader decade page for your age — built around the new baseline, not the recovery transition.",
        ],
        bullets: [
          "Cycle and HPA axis recovery is typically a 6–12 month arc; symptom persistence past that warrants reassessment, not patience.",
          "Future pregnancy planning resets the contraindication list — confirm timing before any compound.",
          "Once stable, the relevant guide is the decade page for your age:",
        ],
      },
    ],
    faqs: [
      {
        question: "When can I start peptides after giving birth?",
        answer: "Standard guidance is to wait until your six-week postpartum clearance and until you have stopped breastfeeding. The exception is if a clinician specifically prescribes a peptide-class medication during this window.",
      },
      {
        question: "Will GHK-Cu reverse stretch marks?",
        answer: "GHK-Cu can improve the appearance of mature stretch marks (months-old, white-pink) by stimulating collagen and dermal remodeling. Improvement is gradual and partial. Fresh red stretch marks respond better than older white ones.",
      },
      {
        question: "Are GLP-1s safe for postpartum weight loss?",
        answer: "GLP-1s are contraindicated during breastfeeding. After weaning, they can be considered, but rapid weight loss may not be the desired postpartum metabolic strategy. Coordinate with your obstetrician or primary care clinician.",
      },
    ],
    siblings: [
      { slug: "women-in-their-30s", title: "Peptides for Women in Their 30s", audience: "Women 30–39" },
      { slug: "women-in-their-20s", title: "Peptides for Women in Their 20s", audience: "Women 20–29" },
      { slug: "pcos", title: "Peptides for PCOS", audience: "Women with PCOS" },
    ],
    relatedGoalIds: ["recovery", "skin_hair", "anxiety"],
  },

  {
    id: "low-testosterone",
    slug: "low-testosterone",
    cluster: "life-stage",
    audience: "Men with low testosterone",
    audienceChips: ["Male", "Low T", "Hormonal"],
    ageRange: "45-54",
    sex: "male",
    seoTitle: "Peptides for Low Testosterone (2026)",
    seoDescription:
      "Three compounds for men with low T: libido restoration, muscle support, and GH-axis optimization. Coordinated with TRT, not as a replacement.",
    h1: "Peptides for Low Testosterone",
    canonicalPath: "/blog/peptides-for/low-testosterone",
    primaryKeyword: "peptides for low testosterone",
    medicalCondition: "Male Hypogonadism",
    heroEyebrow: "Life stage · Low T",
    heroSummary:
      "Peptides do not replace TRT — they complement it. Three compounds address libido, muscle, and GH-axis recovery alongside or instead of testosterone therapy.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Peptides cannot raise endogenous testosterone meaningfully — they address downstream effects of low T (libido, muscle loss, GH suppression). PT-141 for libido, a GH secretagogue for muscle preservation, and a recovery compound form the typical three-front complement to TRT.",
    safetyFlags: [
      {
        label: "Confirm low T with labs first",
        detail: "Total and free testosterone, SHBG, LH, FSH on two morning draws. Many 'low T' complaints reflect lifestyle factors.",
        severity: "warning",
      },
      {
        label: "Coordinate with your prescriber",
        detail: "Peptides + TRT requires shared planning so labs reflect the combined picture.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "sexual_health", framing: "Libido is often the first complaint and the slowest to respond to TRT alone — central-acting compounds like PT-141 fill the gap." },
      { goalId: "muscle_growth", framing: "Lean mass loss from chronic low T is hard to reverse on testosterone replacement alone — GH-axis support accelerates the recovery." },
      { goalId: "gh_optimization", framing: "Low T often coexists with suppressed GH pulses; addressing both axes produces a more complete restoration." },
    ],
    whyDifferent: {
      intro: "Low T is a hormonal diagnosis, not a peptide problem. The honest framing: peptides are adjuncts to TRT, not substitutes for it.",
      points: [
        "Peptides do not meaningfully raise endogenous testosterone — they act on growth hormone, soft tissue, and CNS arousal pathways.",
        "Libido often lags testosterone normalization on TRT by weeks to months; PT-141 acts more rapidly via melanocortin receptors.",
        "Chronic low T suppresses the GH axis as well; secretagogue compounds help recover both signals.",
      ],
    },
    bodySections: [
      {
        id: "trt-or-peptides",
        eyebrow: "Decision",
        title: "TRT or peptides — or both?",
        paragraphs: [
          "If labs confirm clinically low testosterone with symptoms, TRT is the first-line treatment. Peptides on their own will not restore the testosterone axis. The combined protocol — TRT for the hormone, peptides for downstream symptoms — is more complete than either alone.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides actually help",
        title: "What peptides add to a hypogonadism workup",
        paragraphs: [
          "Peptides do not treat low testosterone — they treat the downstream symptoms that TRT alone may not fully resolve. The case for adding them is specific: libido that persists despite optimized TRT, recovery deficits that bloodwork-normalized testosterone has not fixed, and body composition shifts that demand a different lever. None of these justify peptides as a TRT substitute.",
        ],
        bullets: [
          "Libido or arousal complaints persisting on optimized TRT — PT-141 acts on a CNS pathway independent of testosterone.",
          "Recovery and soft-tissue deficits despite normalized free T — BPC-157 has a clean case.",
          "Body composition resistance — GH secretagogues address a separate axis from testosterone.",
          "If TRT has not been started and labs justify it, do that first; do not substitute peptides for hormone replacement.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline alongside endocrine care",
        paragraphs: [
          "Low-testosterone protocols must coexist with the endocrinologist or men's-health clinician managing your TRT. The dominant rule: every peptide is discussed with the prescriber, every cycle has lab follow-up, and nothing substitutes for the underlying hormone replacement. Solo peptide experimentation while on TRT is the most common mistake.",
        ],
        bullets: [
          "Disclose every peptide to your TRT prescriber — even short courses.",
          "Repeat full hormonal panel every 3 months on combined protocols: total + free T, SHBG, LH, FSH, estradiol, HCT, PSA.",
          "Avoid stacking GH-axis compounds with TRT unless coordinated — IGF-1 monitoring becomes essential.",
          "If considering fertility-preserving alternatives (hCG, gonadorelin, enclomiphene), let your prescriber lead the protocol — these are clinical, not research.",
        ],
      },
      {
        id: "what-peptides-do-not-fix",
        eyebrow: "Realistic ceiling",
        title: "What peptides will not do for low testosterone",
        paragraphs: [
          "The most common low-T mistake is reaching for peptides because TRT feels like a long-term commitment. Peptides do not raise sustained testosterone, do not restore HPG axis function in primary hypogonadism, and do not substitute for the long arc of hormonal replacement. Setting that expectation early prevents wasted cycles and bloodwork.",
        ],
        bullets: [
          "Peptides do not raise sustained testosterone — kisspeptin and gonadorelin give short pulses, not chronic elevation.",
          "Peptides do not restore primary hypogonadism (testicular failure) — the upstream signal is intact but the response is not.",
          "Peptides do not replace the bone, cardiovascular, and metabolic benefits of normalized testosterone.",
          "If a clinician has recommended TRT, the right question is how to optimize it — not whether to substitute peptides.",
        ],
      },
    ],
    faqs: [
      {
        question: "Can peptides raise testosterone?",
        answer: "Not meaningfully. Kisspeptin and gonadorelin can stimulate LH and downstream testosterone, but the effects are short-lived and not standard treatment for hypogonadism. For sustained testosterone elevation, TRT or hCG protocols remain first-line.",
      },
      {
        question: "Will peptides cause testicular atrophy like TRT can?",
        answer: "No. The peptide classes used for low-T downstream symptoms (PT-141, GH secretagogues, BPC-157) do not suppress LH or FSH. Testicular atrophy on TRT is from exogenous testosterone suppressing the HPG axis — peptides do not do this.",
      },
      {
        question: "How long until libido improves on PT-141?",
        answer: "PT-141 acts within hours of subcutaneous administration. It is typically used acutely (45–90 minutes before planned intimacy) rather than on a continuous schedule. Most users notice effect on the first or second dose.",
      },
    ],
    siblings: [
      { slug: "men-over-40", title: "Peptides for Men Over 40", audience: "Men 40–49" },
      { slug: "men-over-50", title: "Peptides for Men Over 50", audience: "Men 50–59" },
      { slug: "men-over-60", title: "Peptides for Men Over 60", audience: "Men 60+" },
    ],
    relatedGoalIds: ["sexual_health", "muscle_growth", "gh_optimization"],
  },

  // ──────────────────────────────────────────────────────────────────
  // METABOLIC / ENDOCRINE CONDITION
  // ──────────────────────────────────────────────────────────────────
  {
    id: "pcos",
    slug: "pcos",
    cluster: "condition",
    audience: "Women with PCOS",
    audienceChips: ["Female", "PCOS", "Metabolic"],
    ageRange: "25-34",
    sex: "female",
    seoTitle: "Peptides for PCOS (2026)",
    seoDescription:
      "Two compounds for PCOS: evidence-backed fat loss and skin support. Coordinated with insulin-sensitizing medications, not a replacement.",
    h1: "Peptides for PCOS",
    canonicalPath: "/blog/peptides-for/pcos",
    primaryKeyword: "peptides for pcos",
    medicalCondition: "Polycystic Ovary Syndrome",
    heroEyebrow: "Condition · PCOS",
    heroSummary:
      "PCOS combines insulin resistance, androgen excess, and ovulatory dysfunction. Two compounds — fat loss and skin — address the symptoms peptides reach without overstepping endocrine care.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "PCOS is best managed by insulin-sensitizing medication, weight loss when indicated, and androgen-targeted treatment. A GLP-1 has growing evidence for PCOS-related weight loss; GHK-Cu can address hair and skin manifestations. Both complement, not replace, endocrine care.",
    safetyFlags: [
      {
        label: "Endocrine care is first-line",
        detail: "Metformin, hormonal contraception, or specific anti-androgens remain first-line — peptides are adjuncts.",
        severity: "warning",
      },
      {
        label: "Pregnancy considerations",
        detail: "If you have PCOS and are trying to conceive, discontinue GLP-1s 2 months before attempting.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "fat_loss", framing: "Insulin resistance drives the PCOS phenotype; GLP-1s improve both weight and insulin sensitivity, which can restore ovulation in some patients." },
      { goalId: "skin_hair", framing: "Hirsutism, acne, and scalp hair thinning are common PCOS cosmetic manifestations — GHK-Cu has the cleanest mechanism for skin support." },
    ],
    whyDifferent: {
      intro: "PCOS is an endocrine diagnosis, not a peptide one. The most effective treatments remain metformin, hormonal management, and weight loss when applicable. Peptides reach a subset of symptoms.",
      points: [
        "Insulin resistance is the metabolic engine of PCOS — improving it improves nearly every downstream feature.",
        "Androgen excess drives the cosmetic symptoms (acne, hirsutism, hair thinning) that often distress patients most.",
        "Weight loss as small as 5–10% restores ovulation in many PCOS patients with overweight phenotypes.",
      ],
    },
    bodySections: [
      {
        id: "glp1-pcos",
        eyebrow: "GLP-1 evidence",
        title: "GLP-1 evidence for PCOS",
        paragraphs: [
          "GLP-1 receptor agonists improve weight, insulin sensitivity, and ovulatory function in PCOS in multiple human trials. They are not currently FDA-approved for PCOS specifically, but use is widespread among endocrinologists treating overweight PCOS patients. Coordinate with your endocrinologist before starting.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides actually help",
        title: "Indications that earn a protocol with PCOS",
        paragraphs: [
          "PCOS is a clinical syndrome, not a peptide-treatable condition. Peptides earn a place where they address a specific PCOS-driven outcome — weight that has resisted dialed-in lifestyle inputs, insulin resistance not controlled by metformin alone, persistent anxiety, or recovery deficits. Each compound rides alongside endocrinologist-led care, not as a substitute.",
        ],
        bullets: [
          "Overweight phenotype with weight that has resisted 12+ weeks of dialed-in inputs plus metformin — GLP-1s have the strongest evidence, endocrinologist-led.",
          "Persistent insulin resistance markers (HOMA-IR, fasting insulin) on metformin alone — incretins enter the conversation.",
          "Acute anxiety unresponsive to lifestyle, where benzodiazepine dependence is a concern — Selank has a case.",
          "Active fertility planning — most research peptides are contraindicated; coordinate timing with your reproductive endocrinologist.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline alongside PCOS care",
        paragraphs: [
          "PCOS protocols must coexist with the endocrinologist or reproductive-medicine clinician managing the syndrome. The dominant rule: every peptide is discussed with the prescriber, fertility timing dictates the cycle list, and lifestyle inputs remain the foundation. Solo peptide protocols layered onto unmanaged PCOS create more variables than they solve.",
        ],
        bullets: [
          "Disclose every peptide to your endocrinologist or reproductive-medicine clinician.",
          "Repeat full panel every 3 months — fasting glucose, insulin, HbA1c, lipid panel, free + total testosterone, SHBG, LH, FSH.",
          "Discontinue GLP-1s at least 2 months before any conception attempt.",
          "Track menstrual cycle alongside any protocol — pattern change is a hold-and-reassess trigger.",
        ],
      },
      {
        id: "fertility-context",
        eyebrow: "If fertility is the goal",
        title: "When PCOS treatment is fertility-driven",
        paragraphs: [
          "Fertility-driven PCOS care has different priorities than weight-driven PCOS care. The dominant levers shift from weight loss and insulin sensitivity to ovulation induction and uterine receptivity. Peptides have minimal role in fertility-direct treatment; most are contraindicated during conception attempts and pregnancy.",
        ],
        bullets: [
          "Fertility-direct treatment (letrozole, gonadotropin protocols, IVF) is reproductive-endocrinology territory — peptides do not substitute.",
          "GLP-1s must be discontinued at least 2 months before attempted conception.",
          "BPC-157 and similar compounds have no fertility data and are typically held during active conception attempts.",
          "Once family planning is complete, the broader PCOS protocol re-opens.",
        ],
      },
    ],
    faqs: [
      {
        question: "Will peptides cure PCOS?",
        answer: "No. PCOS is a chronic condition managed, not cured. The compounds discussed here address specific symptoms — insulin resistance, weight, skin — but do not eliminate the underlying syndrome.",
      },
      {
        question: "Can I take a GLP-1 if I am trying to conceive?",
        answer: "No. GLP-1s should be discontinued at least 2 months before attempting conception. If PCOS-related weight loss is part of your fertility plan, complete the weight loss phase and then taper off before active conception attempts.",
      },
      {
        question: "Will peptides help with PCOS-related acne?",
        answer: "Indirectly. Anti-androgens and combined oral contraceptives are first-line for PCOS acne. GHK-Cu topically may support skin repair and improve scarring, but it does not address the androgen-driven acne itself.",
      },
    ],
    siblings: [
      { slug: "women-in-their-20s", title: "Peptides for Women in Their 20s", audience: "Women 20–29" },
      { slug: "women-in-their-30s", title: "Peptides for Women in Their 30s", audience: "Women 30–39" },
      { slug: "insulin-resistance", title: "Peptides for Insulin Resistance", audience: "Insulin-resistant adults" },
      { slug: "diabetics", title: "Peptides for Diabetics", audience: "Diabetics" },
    ],
    relatedGoalIds: ["fat_loss", "skin_hair"],
  },

  {
    id: "diabetics",
    slug: "diabetics",
    cluster: "condition",
    audience: "Diabetics",
    audienceChips: ["Type 2", "Metabolic", "Endocrine"],
    ageRange: "45-54",
    sex: "any",
    seoTitle: "Peptides for Diabetics (2026)",
    seoDescription:
      "Two compounds for diabetics: GLP-1-class glucose and weight control, plus recovery support. Coordinated with diabetes care, not substituted for it.",
    h1: "Peptides for Diabetics",
    canonicalPath: "/blog/peptides-for/diabetics",
    primaryKeyword: "peptides for diabetics",
    medicalCondition: "Type 2 Diabetes Mellitus",
    heroEyebrow: "Condition · Diabetes",
    heroSummary:
      "GLP-1 receptor agonists are already standard diabetes care. Two compounds — incretin-class and tissue recovery — address weight, glucose, and the soft-tissue costs of chronic hyperglycemia.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Type 2 diabetes is increasingly managed with GLP-1 and dual-incretin compounds as first-line agents alongside metformin. Tissue recovery support with BPC-157 addresses the slow soft-tissue healing characteristic of chronic hyperglycemia.",
    safetyFlags: [
      {
        label: "Endocrine care comes first",
        detail: "Type 1 and insulin-dependent type 2 diabetes require professional management. Peptides do not replace insulin.",
        severity: "danger",
      },
      {
        label: "Watch for hypoglycemia",
        detail: "GLP-1s combined with sulfonylureas or insulin substantially increase hypoglycemia risk.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "fat_loss", framing: "GLP-1 and dual-incretin compounds improve glycemic control and produce weight loss simultaneously — they have moved to first-line for type 2 diabetes." },
      { goalId: "recovery", framing: "Chronic hyperglycemia slows soft-tissue healing measurably; BPC-157 has data for diabetic-context wound and tissue repair." },
    ],
    whyDifferent: {
      intro: "Diabetes is the one condition where peptides are not adjunct — they are increasingly first-line.",
      points: [
        "Semaglutide and tirzepatide are FDA-approved for type 2 diabetes and outperform older oral agents on glycemic control.",
        "Diabetic wound healing is impaired; BPC-157 has preclinical evidence for accelerating diabetic ulcer and soft-tissue repair.",
        "Both peptide classes work alongside metformin, with combined therapy reducing cardiovascular events in clinical trials.",
      ],
    },
    bodySections: [
      {
        id: "coordinate-care",
        eyebrow: "Coordination",
        title: "Coordinate everything with your endocrinologist",
        paragraphs: [
          "Diabetes is the highest-stakes context for compound coordination. Starting a GLP-1 while on sulfonylureas or insulin requires dose adjustment to prevent hypoglycemia. Adding BPC-157 to a diabetic wound regimen should be communicated to your wound care team.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides actually help",
        title: "Indications that earn a protocol in diabetes",
        paragraphs: [
          "In type 2 diabetes, GLP-1 receptor agonists are not a peptide curiosity — they are a mainstay of guideline-directed care. Other peptides earn a place narrowly: BPC-157 for documented diabetic wound healing in coordination with wound care, recovery compounds for the increased physical demands of glucose management. Anti-aging and aesthetic protocols are not the case.",
        ],
        bullets: [
          "Type 2 diabetes with overweight phenotype — GLP-1 receptor agonists are first-line, endocrinologist-prescribed.",
          "Diabetic wound that has stalled in standard care — BPC-157 is investigational adjunct, never substitute.",
          "Cardiovascular risk reduction is needed — GLP-1s have outcomes data beyond glucose; coordinate the picture with your prescriber.",
          "Type 1 diabetes — GLP-1s are not first-line; coordinate any compound carefully with insulin dosing.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline at the highest-stakes coordination level",
        paragraphs: [
          "Diabetic protocols are the highest-stakes context for peptide coordination. The same compound that is forgiving in a healthy adult can drive hypoglycemia, alter insulin requirements, or interact with diabetes medications in ways that change daily dosing. Solo peptide experimentation while on insulin or sulfonylureas is not appropriate.",
        ],
        bullets: [
          "Every peptide gets disclosed to your endocrinologist before starting — no exceptions.",
          "Continuous glucose monitor or frequent fingerstick monitoring through the first 4 weeks of any new compound.",
          "Sulfonylurea or insulin dose almost always needs reduction when starting a GLP-1 — coordinate proactively.",
          "Repeat HbA1c, lipid panel, kidney function (eGFR, urine ACR), and liver enzymes every 3 months.",
        ],
      },
      {
        id: "comorbidity-context",
        eyebrow: "Diabetes-adjacent conditions",
        title: "Why diabetes-adjacent care matters",
        paragraphs: [
          "Diabetes rarely exists alone. Hypertension, dyslipidemia, kidney disease, retinopathy, and neuropathy each change which compounds are appropriate. The right protocol is the one that fits the full clinical picture — including comorbidities and medications that may not feel related to the peptide decision but are.",
        ],
        bullets: [
          "Kidney function (eGFR, ACR) — GLP-1 dosing and other compound choices change at lower eGFR.",
          "Cardiovascular workup — current ECG, stress test if indicated, lipid optimization.",
          "Retinopathy screening — rapid HbA1c drops on incretins can transiently worsen retinopathy in some patients.",
          "Neuropathy — affects wound and recovery decisions, particularly around BPC-157.",
        ],
      },
    ],
    faqs: [
      {
        question: "Can peptides replace insulin?",
        answer: "No. Type 1 diabetics and insulin-dependent type 2 diabetics require insulin. GLP-1s reduce insulin requirements in some type 2 patients but do not eliminate the need entirely in advanced disease.",
      },
      {
        question: "Is semaglutide safer than metformin?",
        answer: "Different risk profiles. Metformin has a 60-year safety record and is inexpensive. Semaglutide has more dramatic glycemic and weight effects with a different side effect profile (GI symptoms, gallbladder, pancreatitis risk). Most modern protocols use both.",
      },
      {
        question: "Will BPC-157 help diabetic foot ulcers?",
        answer: "Preclinical evidence supports accelerated wound healing in diabetic context. Human clinical evidence is limited. Standard diabetic wound care (offloading, debridement, infection control) remains first-line — BPC-157 is investigational adjunct.",
      },
    ],
    siblings: [
      { slug: "insulin-resistance", title: "Peptides for Insulin Resistance", audience: "Insulin-resistant adults" },
      { slug: "obesity", title: "Peptides for Obesity", audience: "Obese adults" },
      { slug: "pcos", title: "Peptides for PCOS", audience: "Women with PCOS" },
    ],
    relatedGoalIds: ["fat_loss", "recovery"],
  },

  {
    id: "insulin-resistance",
    slug: "insulin-resistance",
    cluster: "condition",
    audience: "Insulin-resistant adults",
    audienceChips: ["Prediabetes", "Metabolic", "Visceral fat"],
    ageRange: "45-54",
    sex: "any",
    seoTitle: "Peptides for Insulin Resistance (2026)",
    seoDescription:
      "Two compounds for insulin resistance: GLP-1-class glucose control and longevity-leaning support. The pre-diabetes window where peptides have their strongest case.",
    h1: "Peptides for Insulin Resistance",
    canonicalPath: "/blog/peptides-for/insulin-resistance",
    primaryKeyword: "peptides for insulin resistance",
    medicalCondition: "Insulin Resistance",
    heroEyebrow: "Condition · Insulin resistance",
    heroSummary:
      "Insulin resistance is the prediabetes window — where intervention has the highest leverage. Two compounds address the metabolic shift and the systemic aging signal it drives.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Insulin resistance is the metabolic phase before type 2 diabetes — and where intervention reverses the trajectory. A GLP-1 reduces visceral fat and insulin demand directly; a longevity-leaning compound supports the systemic aging signal that hyperinsulinemia drives.",
    safetyFlags: [
      {
        label: "Get fasting insulin, not just glucose",
        detail: "Fasting glucose can be normal while fasting insulin is elevated for years. Test both.",
        severity: "info",
      },
    ],
    priorityGoals: [
      { goalId: "fat_loss", framing: "Insulin resistance and visceral fat are mechanically linked — reducing one improves the other directly." },
      { goalId: "anti_aging", framing: "Chronic hyperinsulinemia is a primary driver of accelerated aging; addressing it has system-wide longevity effects." },
    ],
    whyDifferent: {
      intro: "Insulin resistance is the most reversible major chronic-disease precursor. The protocol is biased toward early, sustained intervention.",
      points: [
        "Fasting insulin elevation often precedes elevated glucose by 5–10 years — the window where intervention is most effective.",
        "Visceral fat and insulin resistance reinforce each other; breaking the loop early prevents diabetes progression.",
        "Many longevity peptides (MOTS-c, mitochondrial-targeted compounds) work in part by improving insulin sensitivity.",
      ],
    },
    bodySections: [
      {
        id: "lifestyle-first",
        eyebrow: "First lever",
        title: "Lifestyle still does more than any peptide",
        paragraphs: [
          "Resistance training, a high-protein diet, and 7+ hours of sleep are still the most powerful interventions for insulin resistance. Peptides accelerate and supplement — they do not substitute. Walk after meals. Lift heavy 3× per week. Sleep enough. Then add compounds.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides actually help",
        title: "Indications that justify a compound for insulin resistance",
        paragraphs: [
          "Insulin resistance is a marker, not a destination. The dominant levers are lifestyle and (when indicated) metformin. Peptides earn a place when metabolic markers stay elevated despite dialed-in lifestyle, when prediabetic trajectories warrant intervention, or when a coexisting condition (PCOS, perimenopausal weight redistribution) raises the urgency.",
        ],
        bullets: [
          "Metabolic markers (HOMA-IR, fasting insulin, ApoB) elevated despite 12+ weeks of dialed-in lifestyle and metformin.",
          "Prediabetic trajectory (HbA1c 5.7–6.4) where lifestyle plus metformin is not closing the gap — GLP-1s, clinician-led.",
          "Coexisting PCOS or perimenopausal redistribution amplifying the insulin signal.",
          "Visceral fat distribution that resists diet alone — incretin-class compounds enter the conversation.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline before T2D crystallizes",
        paragraphs: [
          "The insulin-resistance window is the prevention window. Aggressive intervention now beats trying to reverse type 2 diabetes later. The protocol logic is conservative dosing, frequent measurement, and ruthless prioritization of the lifestyle inputs that move the needle independent of any compound.",
        ],
        bullets: [
          "Repeat HOMA-IR, fasting insulin, HbA1c, lipid panel including ApoB every 3 months on any active protocol.",
          "Add resistance training before any compound — it improves insulin sensitivity independent of weight loss.",
          "Coordinate with primary care; flag interactions with metformin, blood pressure medications, statins.",
          "Track waist-to-height ratio in addition to weight — distribution matters more than total mass for IR.",
        ],
      },
      {
        id: "bridge-to-diabetes",
        eyebrow: "What changes if T2D develops",
        title: "How the protocol changes if you cross into diabetes",
        paragraphs: [
          "If HbA1c crosses into the diabetic range (6.5+), the protocol changes from prevention to management. Endocrinology coordination becomes mandatory, dosing decisions move out of solo territory, and the broader cardiovascular and kidney workup becomes a standing part of the picture.",
        ],
        bullets: [
          "HbA1c 6.5+ on two readings is the diabetes threshold — coordinate care with endocrinology.",
          "Insulin and sulfonylurea protocols layer additional coordination complexity onto every peptide decision.",
          "Cardiovascular and kidney monitoring shift from optional to mandatory.",
          "Read on once T2D develops:",
        ],
      },
    ],
    faqs: [
      {
        question: "Will a GLP-1 fix insulin resistance?",
        answer: "GLP-1s improve insulin sensitivity substantially, in part through weight loss and in part through direct effects on incretin signaling. They do not 'cure' insulin resistance — discontinuing typically returns the metabolic profile toward baseline unless lifestyle has changed.",
      },
      {
        question: "Should I take metformin or a peptide?",
        answer: "Metformin is inexpensive, 60-year safety record, and first-line for early insulin resistance. GLP-1s have stronger weight effects but more side effects and higher cost. Many protocols use both. Your prescriber should make this call.",
      },
      {
        question: "How do I know if I am insulin resistant?",
        answer: "Fasting insulin > 10 µIU/mL, HOMA-IR > 2.0, or triglyceride-to-HDL ratio > 2.0 all suggest insulin resistance. A continuous glucose monitor can also reveal post-meal spikes that fasting glucose misses.",
      },
    ],
    siblings: [
      { slug: "diabetics", title: "Peptides for Diabetics", audience: "Diabetics" },
      { slug: "obesity", title: "Peptides for Obesity", audience: "Obese adults" },
      { slug: "pcos", title: "Peptides for PCOS", audience: "Women with PCOS" },
      { slug: "women-over-40", title: "Peptides for Women Over 40", audience: "Women 40–49" },
    ],
    relatedGoalIds: ["fat_loss", "anti_aging"],
  },

  {
    id: "obesity",
    slug: "obesity",
    cluster: "condition",
    audience: "Obese adults",
    audienceChips: ["BMI 30+", "Metabolic", "Weight loss"],
    ageRange: "45-54",
    sex: "any",
    seoTitle: "Peptides for Obesity (2026)",
    seoDescription:
      "Two compounds for obesity: GLP-1 and dual-incretin weight loss, plus BPC-157 for joint recovery. Evidence-graded and matched to clinical obesity.",
    h1: "Peptides for Obesity",
    canonicalPath: "/blog/peptides-for/obesity",
    primaryKeyword: "peptides for obesity",
    medicalCondition: "Obesity",
    heroEyebrow: "Condition · Obesity",
    heroSummary:
      "GLP-1 and dual-incretin compounds have changed obesity treatment more in the last 5 years than the previous 40. Two compounds — incretin-class and joint recovery — match the medical and mobility load.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Clinical obesity (BMI 30+) is now treatable with GLP-1 and dual-incretin compounds that produce 15–22% sustained weight loss in clinical trials. BPC-157 addresses the joint and soft-tissue load that obesity places on the body during the loss phase.",
    safetyFlags: [
      {
        label: "Coordinate with a clinician",
        detail: "GLP-1s require dose titration, monitoring, and discontinuation planning — not a self-managed protocol.",
        severity: "warning",
      },
      {
        label: "Protein and resistance training are not optional",
        detail: "Lean mass loss on GLP-1s can be substantial without high protein intake and resistance training.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "fat_loss", framing: "GLP-1 and dual-incretin compounds produce 15–22% sustained weight loss in clinical trials — the largest shift in obesity treatment in decades." },
      { goalId: "recovery", framing: "Carrying excess weight loads joints continuously; BPC-157 addresses the soft-tissue maintenance burden during and after weight loss." },
    ],
    whyDifferent: {
      intro: "Obesity is no longer a willpower problem to be lectured at. Modern treatment is pharmaceutical — and effective.",
      points: [
        "STEP and SURMOUNT trials demonstrated 15–22% sustained weight loss with semaglutide and tirzepatide respectively — comparable to bariatric surgery for many patients.",
        "Weight regain after discontinuation is substantial; most patients require continued therapy to maintain losses.",
        "Lean mass loss can reach 30–40% of total weight lost without resistance training and high protein intake.",
      ],
    },
    bodySections: [
      {
        id: "protect-muscle",
        eyebrow: "Protect lean mass",
        title: "Protein, lifting, and weight loss in parallel",
        paragraphs: [
          "The single biggest mistake on GLP-1s is losing muscle alongside fat. Aim for 1 gram of protein per pound of target body weight, resistance train at least 3× per week, and track lean mass with a DEXA or BIA scan every 8–12 weeks. The goal is fat loss, not weight loss in the abstract.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides actually help",
        title: "Indications and clinical thresholds",
        paragraphs: [
          "Obesity treatment is now a pharmaceutical discipline with clear guideline-directed thresholds. The case for a GLP-1 is no longer cosmetic — it is clinical, with cardiovascular and metabolic outcomes data. The decision is when and which compound, not whether to use peptides.",
        ],
        bullets: [
          "BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity — guideline threshold for pharmacotherapy.",
          "Tirzepatide vs semaglutide: comparable safety, larger weight-loss effect for tirzepatide; price and access often dictate choice.",
          "BPC-157 as adjunct for joint loading complaints during rapid weight loss — short courses, training-coordinated.",
          "Bariatric surgery candidacy — coordinate with surgical team; peptide use after surgery has specific protocols.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline for a multi-year arc",
        paragraphs: [
          "Modern obesity treatment is a multi-year arc, not a cycle. Weight regain after discontinuation is the rule in clinical trials. Plan dosing, monitoring, and transition off as a single long protocol — and protect lean mass aggressively throughout, because the lean mass you lose at 40 does not fully return.",
        ],
        bullets: [
          "Titrate slowly per label — the most common failure is escalating too fast and dropping out from GI side effects.",
          "Repeat full panel every 3 months — fasting glucose, HbA1c, lipid panel with ApoB, kidney function, liver enzymes.",
          "DEXA or BIA at baseline and every 8–12 weeks — track lean mass loss as carefully as fat loss.",
          "Coordinate with primary care; flag interactions with BP medications, statins, and any psychiatric medications.",
        ],
      },
      {
        id: "post-target-context",
        eyebrow: "After reaching target",
        title: "What changes when you reach a stable weight",
        paragraphs: [
          "Reaching target weight is the start of the maintenance arc, not the end of treatment. Maintenance protocols are individual — some patients transition to lower-dose maintenance, others stay at therapeutic dose indefinitely. The same monitoring cadence applies; the same lifestyle inputs remain non-negotiable.",
        ],
        bullets: [
          "Maintenance dosing decisions belong to your prescriber — discontinuation typically leads to regain.",
          "Resistance training and high protein intake stay non-negotiable through maintenance.",
          "Body composition monitoring continues every 3–6 months.",
          "Read on for the related insulin-resistance trajectory:",
        ],
      },
    ],
    faqs: [
      {
        question: "How long do I need to stay on a GLP-1?",
        answer: "For most patients, indefinitely. Weight regain after discontinuation is the norm in clinical trials. Some patients can transition to lower-dose maintenance once at target weight, but this requires careful clinician guidance.",
      },
      {
        question: "Will I lose muscle on a GLP-1?",
        answer: "Yes, some. Lean mass loss accounts for 25–40% of total weight lost depending on protein intake and resistance training. Active patients with high protein intake preserve significantly more muscle than sedentary ones.",
      },
      {
        question: "Is tirzepatide better than semaglutide?",
        answer: "In head-to-head trials (SURMOUNT-5, 2024), tirzepatide produced greater weight loss than semaglutide at comparable durations. Side effect profiles are similar. Insurance coverage and cost often drive the practical choice.",
      },
    ],
    siblings: [
      { slug: "diabetics", title: "Peptides for Diabetics", audience: "Diabetics" },
      { slug: "insulin-resistance", title: "Peptides for Insulin Resistance", audience: "Insulin-resistant adults" },
      { slug: "men-over-40", title: "Peptides for Men Over 40", audience: "Men 40–49" },
      { slug: "women-over-40", title: "Peptides for Women Over 40", audience: "Women 40–49" },
    ],
    relatedGoalIds: ["fat_loss", "recovery"],
  },

  // ──────────────────────────────────────────────────────────────────
  // ATHLETES
  // ──────────────────────────────────────────────────────────────────
  {
    id: "bodybuilders",
    slug: "bodybuilders",
    cluster: "athlete",
    audience: "Bodybuilders",
    audienceChips: ["Hypertrophy", "Competitive", "Recomp"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Bodybuilders (2026)",
    seoDescription:
      "Three compounds for bodybuilders: muscle growth, fat loss, and recovery — matched to the bulk-cut-recover cycle.",
    h1: "Peptides for Bodybuilders",
    canonicalPath: "/blog/peptides-for/bodybuilders",
    primaryKeyword: "peptides for bodybuilders",
    heroEyebrow: "Athlete · Bodybuilding",
    heroSummary:
      "Bodybuilding maps cleanly to three goals. One compound each for muscle, fat, and recovery — sized to the cycle phase, not the buffet.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Competitive and serious bodybuilders cycle through bulk, cut, and recover phases. One compound per phase — a growth factor for the gain phase, an incretin or fat-loss compound for the cut, and a tissue-repair compound for off-season recovery — covers the protocol without polypharmacy.",
    safetyFlags: [
      {
        label: "WADA prohibition",
        detail: "Almost every growth-related peptide is on the WADA prohibited list. Tested athletes should consult their federation's banned list first.",
        severity: "danger",
      },
    ],
    priorityGoals: [
      { goalId: "muscle_growth", framing: "Growth factor and GH-axis compounds shorten the time from training stimulus to recovered tissue, which is the rate-limiting step in hypertrophy." },
      { goalId: "fat_loss", framing: "Contest prep and aggressive cuts benefit from incretin or fat-loss compounds that preserve more lean mass than caloric restriction alone." },
      { goalId: "recovery", framing: "Off-season recovery determines how aggressively you can train next cycle — soft-tissue compounds protect the investment." },
    ],
    whyDifferent: {
      intro: "Bodybuilding is a cyclical sport. The protocol changes with the phase, not the season.",
      points: [
        "Growth factor compounds (IGF-1 LR3, MGF) have direct muscle hypertrophy mechanisms but carry significant risk and WADA status.",
        "Fat loss compounds during contest prep need to spare lean mass — incretin class beats stimulant-class on this metric.",
        "Off-season recovery is the longest phase and the highest-leverage one — most lifetime gains accumulate here, not in peak weeks.",
      ],
    },
    bodySections: [
      {
        id: "tested-vs-untested",
        eyebrow: "Compliance",
        title: "Tested vs untested athletes — different protocols",
        paragraphs: [
          "If you compete in a tested federation, almost every growth-related compound is banned. BPC-157 sits in a gray zone (not explicitly named but covered by general prohibitions). The protocol design changes substantially based on tested status — verify your federation's banned list before any compound choice.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn their place",
        title: "What peptides actually do for bodybuilders",
        paragraphs: [
          "Peptides do not substitute for the inputs that drive bodybuilding outcomes: training stimulus, total daily protein, calorie surplus or deficit, and sleep. They earn space when training volume has plateaued specific recovery markers, when a discrete injury threatens a contest prep, or when a cutting phase needs lean mass protection. Reaching for peptides because gym crowd talk says to is not a case.",
        ],
        bullets: [
          "Recurring tendon or joint issue from training volume — BPC-157 has the strongest case here.",
          "Recovery markers (sleep, HRV, training tolerance) trending poorly into a cutting phase — short GH-secretagogue block, training-coordinated.",
          "Cutting phase where lean mass loss is the limiting factor — GH-axis support with strict protein and resistance volume.",
          "Documented injury threatening contest prep — BPC-157 with rehab, not as a substitute for it.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline through training blocks",
        paragraphs: [
          "Bodybuilding protocols benefit most from cycle synchronization — match peptide blocks to training phases (volume, intensity, peak, transition), not to vague monthly cadence. Bloodwork is non-negotiable; the most common bodybuilding peptide mistake is open-ended use without lab monitoring.",
        ],
        bullets: [
          "Pre-cycle bloodwork: total + free testosterone, SHBG, LH, FSH, estradiol, lipid panel with ApoB, IGF-1, HCT, kidney + liver, fasting glucose.",
          "Repeat at 8 and 16 weeks during any active block.",
          "GH-axis cycles: 8–12 weeks on, 4 weeks off, single compound — do not stack two GH-axis compounds.",
          "Track training, recovery, and physique outcomes weekly — peptide cycles judged by these, not by the compound's reputation.",
        ],
      },
      {
        id: "bridge-to-natural",
        eyebrow: "If you're tested or considering going natural",
        title: "Where the protocol diverges for tested athletes",
        paragraphs: [
          "Tested federations and drug-free competitions have a different protocol logic entirely. The compounds available shrink to a narrow set; the bloodwork, screening, and testing-day timing decisions become the protocol. If competing tested is the path, the natural-bodybuilders page covers the boundary conditions.",
        ],
        bullets: [
          "BPC-157, GHK-Cu, and a handful of recovery compounds remain viable for tested athletes — verify with current WADA prohibited list.",
          "Wash-out times for any prior compound matter — banned-substance residue can persist long after use.",
          "Out-of-competition testing windows mean tested protocols must be clean year-round, not just during the season.",
          "Read on for tested-athlete protocols:",
        ],
      },
    ],
    faqs: [
      {
        question: "Are bodybuilding peptides legal?",
        answer: "Most are not FDA-approved for performance enhancement and exist in a research-only legal gray area. Some (like GLP-1s) are FDA-approved for specific medical indications and can be prescribed off-label. Tested athletes face additional restrictions via WADA.",
      },
      {
        question: "Do I need to cycle off?",
        answer: "GH-axis and growth-factor compounds are typically cycled (8–12 weeks on, 4 weeks off) to allow endogenous pulse recovery. BPC-157 is used in 4–6 week courses for specific injuries. GLP-1s can be run continuously during the cut phase.",
      },
      {
        question: "Will peptides replace anabolic steroids?",
        answer: "No. Peptides act on growth hormone, IGF, and soft tissue pathways — they do not raise testosterone or activate androgen receptors. Their hypertrophic effects are real but smaller in magnitude and slower than anabolic steroids.",
      },
    ],
    siblings: [
      { slug: "natural-bodybuilders", title: "Peptides for Natural Bodybuilders", audience: "Natural BBers" },
      { slug: "crossfitters", title: "Peptides for CrossFitters", audience: "CrossFitters" },
      { slug: "looksmaxxing", title: "Peptides for Looksmaxxing", audience: "Looksmaxxers" },
      { slug: "men-in-their-20s", title: "Peptides for Men in Their 20s", audience: "Men 20–29" },
    ],
    relatedGoalIds: ["muscle_growth", "fat_loss", "recovery"],
  },

  {
    id: "natural-bodybuilders",
    slug: "natural-bodybuilders",
    cluster: "athlete",
    audience: "Natural bodybuilders",
    audienceChips: ["Drug-tested", "Natural", "Hypertrophy"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Natural Bodybuilders (2026)",
    seoDescription:
      "Three compounds for natural bodybuilders: recovery, modest muscle support, and sleep. WADA-aware selection for tested athletes.",
    h1: "Peptides for Natural Bodybuilders",
    canonicalPath: "/blog/peptides-for/natural-bodybuilders",
    primaryKeyword: "peptides for natural bodybuilders",
    heroEyebrow: "Athlete · Natural bodybuilding",
    heroSummary:
      "Tested means almost every flashy compound is off the table. Three compounds — recovery, modest muscle, sleep — cover what's left and what's worth it.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Tested natural bodybuilders should treat WADA's banned list as the floor of protocol design. Recovery compounds and sleep-supporting peptides have the cleanest tested-status profile, with modest muscle support from low-WADA-status options where appropriate.",
    safetyFlags: [
      {
        label: "Check WADA list before any compound",
        detail: "WADA's banned list is updated annually. Even compounds not specifically named may fall under general prohibitions.",
        severity: "danger",
      },
    ],
    priorityGoals: [
      { goalId: "recovery", framing: "Recovery is the only compound category that consistently respects WADA constraints — and it has the highest leverage for natural athletes." },
      { goalId: "muscle_growth", framing: "Modest muscle support compounds with low WADA status can shorten the recovery window without crossing testing thresholds." },
      { goalId: "sleep", framing: "Slow-wave sleep is when most natural hypertrophy actually occurs — protecting it is the highest-leverage non-banned intervention." },
    ],
    whyDifferent: {
      intro: "Natural bodybuilding is constrained optimization. The interesting compounds are mostly banned. The unbanned ones still move the needle if used well.",
      points: [
        "WADA's S2 category (hormones and growth factors) prohibits IGF-1, GH-secretagogues, and most performance peptides outright.",
        "BPC-157 is not explicitly listed but may fall under general 'S0' prohibitions — federation interpretation varies.",
        "Sleep optimization is the most underrated natural-bodybuilding lever — overnight protein synthesis is when growth actually happens.",
      ],
    },
    bodySections: [
      {
        id: "wada-check",
        eyebrow: "Compliance check",
        title: "Before any compound, check three sources",
        paragraphs: [
          "Federation rulebook (e.g., INBF, WNBF, PNBA), the current WADA prohibited list, and your specific testing protocol's substance panel. The gap between 'not on the WADA list' and 'safe to use in your specific federation' can end a career.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "What's even available for natural athletes",
        paragraphs: [
          "The candidate list for tested-natural protocols is short. Almost everything that grows muscle or pulses GH is prohibited. The compounds that pass scrutiny address recovery (soft tissue) and skin — and even those need federation-by-federation verification before use. Build the protocol from the prohibited list backward.",
        ],
        bullets: [
          "BPC-157 — not WADA-named but covered by S0 'non-approved substances' clause; many natural federations explicitly ban it.",
          "GHK-Cu (topical) — generally accepted for skin support but verify with your federation.",
          "TB-500 / thymosin beta-4 — WADA prohibited (S2). Off the menu.",
          "GH secretagogues (CJC-1295, ipamorelin, MK-677) — WADA prohibited. Off the menu.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline at year-round testing exposure",
        paragraphs: [
          "Natural-athlete protocols must hold up to out-of-competition testing, not just contest-day screening. The dominant rule: clean year-round. Wash-out times for any prior compound matter, federation rulebooks change, and a substance that was acceptable last season can be prohibited this one.",
        ],
        bullets: [
          "Out-of-competition testing windows mean every cycle is read against the calendar, not the contest.",
          "Wash-out: minimum 12 months for any GH-axis compound before competing tested; some federations require longer.",
          "Re-verify federation rulebook before each competition season — interpretations shift.",
          "Document every supplement and compound — a contaminated supplement is a failed test you cannot defend.",
        ],
      },
      {
        id: "if-tested-status-changes",
        eyebrow: "If you stop competing tested",
        title: "When the protocol opens up",
        paragraphs: [
          "Once you stop competing tested, the protocol decisions resemble the broader bodybuilder context — a wider compound list, paired with bloodwork and cycle discipline. The transition is not just expanding the list; it is rebuilding the relationship with bloodwork and clinician coordination that tested protocols rarely require.",
        ],
        bullets: [
          "Establish bloodwork baseline (total + free T, SHBG, LH, FSH, estradiol, lipid, IGF-1, HCT) before adding anything.",
          "Coordinate with a clinician familiar with performance compounds — bloodwork interpretation matters.",
          "Read on for the broader bodybuilder protocol:",
        ],
      },
    ],
    faqs: [
      {
        question: "Is BPC-157 banned in tested federations?",
        answer: "BPC-157 is not explicitly named on the WADA prohibited list as of 2026, but it may fall under general 'S0 — non-approved substances' prohibitions. Federation interpretation varies. Most natural federations include BPC-157 on their banned list.",
      },
      {
        question: "Will sleep peptides show up on a drug test?",
        answer: "DSIP, epitalon, and Selank are not currently on the WADA prohibited list. They do not have standard urine or blood test markers in typical doping panels. Federation-specific rules may differ.",
      },
      {
        question: "Can I use any growth hormone peptide and still compete?",
        answer: "No. All growth hormone-releasing peptides (GHRPs, GHRHs, secretagogues) are explicitly banned by WADA. This includes CJC-1295, ipamorelin, hexarelin, tesamorelin, and MK-677.",
      },
    ],
    siblings: [
      { slug: "bodybuilders", title: "Peptides for Bodybuilders", audience: "Bodybuilders" },
      { slug: "crossfitters", title: "Peptides for CrossFitters", audience: "CrossFitters" },
      { slug: "runners", title: "Peptides for Runners", audience: "Runners" },
    ],
    relatedGoalIds: ["recovery", "muscle_growth", "sleep"],
  },

  {
    id: "runners",
    slug: "runners",
    cluster: "athlete",
    audience: "Runners",
    audienceChips: ["Endurance", "Joint stress", "Mileage"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Runners (2026)",
    seoDescription:
      "Two compounds for runners: tendon and joint recovery, plus sleep architecture support. WADA-aware selection for racing athletes.",
    h1: "Peptides for Runners",
    canonicalPath: "/blog/peptides-for/runners",
    primaryKeyword: "peptides for runners",
    heroEyebrow: "Athlete · Endurance",
    heroSummary:
      "Running breaks the same tissues over and over. Two compounds — recovery and sleep — repair the load and protect the overnight rebuild.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "High-volume runners face cumulative tendon, joint, and bone stress that accumulates over years. Tissue-repair compounds during heavy training blocks and sleep architecture support during recovery weeks form the conservative two-compound protocol.",
    safetyFlags: [
      {
        label: "Banned for tested racers",
        detail: "Most growth-related compounds are banned by USADA and WADA. Recovery and sleep compounds sit in a gray zone.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "recovery", framing: "Running's injury profile is cumulative — Achilles, plantar fascia, ITB, and stress fractures all respond to soft-tissue support." },
      { goalId: "sleep", framing: "Endurance recovery is dominated by sleep quality, not just total hours; deep sleep is when tendon and bone repair occur." },
    ],
    whyDifferent: {
      intro: "Runners get injured at the same rate regardless of how careful they are. The protocol is about repair, not performance enhancement.",
      points: [
        "Tendon turnover takes 6–12 months — injuries you sustain this year are the ones you'll feel three marathons from now.",
        "Bone density declines in high-mileage runners despite weight-bearing activity — sleep and recovery support directly affect bone turnover.",
        "Most performance-enhancing compounds are WADA-banned and would end a competitive career if discovered.",
      ],
    },
    bodySections: [
      {
        id: "injury-cycles",
        eyebrow: "Cycling",
        title: "Use compounds during heavy blocks, taper during races",
        paragraphs: [
          "Concentrate BPC-157 use during peak mileage blocks where injury risk is highest. Taper or discontinue 4 weeks before tested races to err on the side of caution. Sleep-supporting peptides have a longer-cycle approach — run them during recovery weeks and easy blocks.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "What peptides actually do for runners",
        paragraphs: [
          "Running outcomes are driven by training load, recovery, sleep, and body composition — not by compounds. Peptides earn space for a narrow set of cases: stalled tendinopathy or soft-tissue injury that has resisted standard rehab, recovery-from-volume markers trending poorly, or specific structural deficits not addressed by training adjustments. They do not substitute for a coach, a plan, or sleep.",
        ],
        bullets: [
          "Documented tendinopathy (Achilles, patellar, plantar fascia) that has not progressed in 6–8 weeks of eccentric rehab — BPC-157 has the cleanest case.",
          "Recovery markers (resting HR, HRV, sleep) trending poorly into a high-volume block — short-cycle support, training-coordinated.",
          "Bone-stress reaction recovery, post-fracture rehab — coordinate with sports medicine.",
          "Performance-enhancement use is prohibited in any tested federation — verify status before any compound.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline against the race calendar",
        paragraphs: [
          "Runner protocols should be designed around the race calendar, not in spite of it. The dominant variables are tested status (USATF, USADA, WADA depending on event), peak mileage blocks, and race timing. The same compound that is reasonable in a base-building block can be questionable two weeks before a key race.",
        ],
        bullets: [
          "Verify WADA / USADA prohibited list against any compound — annual rule changes happen.",
          "Discontinue research peptides at least 4 weeks before any tested race; longer for compounds with detectable metabolites.",
          "Concentrate use in highest-injury-risk blocks (volume peaks, transition from base to speed).",
          "Track sleep, resting HR, HRV alongside training load — recovery markers drive protocol decisions, not race times.",
        ],
      },
      {
        id: "non-peptide-recovery",
        eyebrow: "Inputs that outperform",
        title: "What does more than any compound",
        paragraphs: [
          "The training inputs that drive recovery — sleep, carbohydrate-adequate eating around hard sessions, proper periodization, eccentric rehab for tendinopathy — outperform any peptide protocol by a margin that is not close. Peptides are layered on top of these, never in place.",
        ],
        bullets: [
          "8+ hours of sleep, prioritized during heavy blocks — the single biggest recovery input.",
          "Carbohydrate around key sessions — under-fueling is the most common cause of stalled recovery.",
          "Eccentric loading rehab — non-negotiable for tendon recovery, peptide or not.",
          "Coaching and periodization — the protocol that wastes the least training is the protocol that wins.",
        ],
      },
    ],
    faqs: [
      {
        question: "Will BPC-157 fix my Achilles tendinopathy?",
        answer: "BPC-157 has the strongest tendon recovery evidence of any research peptide, with preclinical data on Achilles, patellar, and rotator cuff models. Combine with eccentric loading rehab — neither alone works as well as together.",
      },
      {
        question: "Can I race on peptides?",
        answer: "If you compete in any USADA, WADA, or USA Track & Field-sanctioned race, almost every growth-related compound is banned. Recovery and sleep compounds (DSIP, BPC-157) are not specifically named on most banned lists but may fall under general prohibitions — check with your federation.",
      },
      {
        question: "Do peptides improve VO2 max?",
        answer: "No research peptide has strong human evidence for direct VO2 max improvement. Indirectly, compounds that improve sleep, recovery, and training capacity may allow more aerobic stimulus over time.",
      },
    ],
    siblings: [
      { slug: "crossfitters", title: "Peptides for CrossFitters", audience: "CrossFitters" },
      { slug: "natural-bodybuilders", title: "Peptides for Natural Bodybuilders", audience: "Natural BBers" },
      { slug: "mma-fighters", title: "Peptides for MMA Fighters", audience: "MMA fighters" },
    ],
    relatedGoalIds: ["recovery", "sleep"],
  },

  {
    id: "crossfitters",
    slug: "crossfitters",
    cluster: "athlete",
    audience: "CrossFitters",
    audienceChips: ["Mixed modal", "High volume", "Recovery-limited"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for CrossFitters (2026)",
    seoDescription:
      "Two compounds for CrossFit athletes: tissue recovery and modest muscle support. Tuned to the mixed-modal volume that defines the sport.",
    h1: "Peptides for CrossFitters",
    canonicalPath: "/blog/peptides-for/crossfitters",
    primaryKeyword: "peptides for crossfitters",
    heroEyebrow: "Athlete · CrossFit",
    heroSummary:
      "CrossFit's injury profile is broader than any other sport. Two compounds — soft-tissue repair and modest muscle support — match the daily-recoverable demand.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 7,
    tldr: "CrossFit athletes train across modalities daily — weightlifting, gymnastics, endurance — producing a recovery debt no single-sport athlete faces. BPC-157 for tissue repair and a moderate muscle support compound form the practical two-front protocol.",
    safetyFlags: [
      {
        label: "Drug-tested at the elite level",
        detail: "CrossFit Games and Sanctional events test under WADA-equivalent protocols. Most growth-related compounds are banned.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "recovery", framing: "CrossFit's mixed-modal volume produces a broader injury surface than any single-sport training — recovery is the bottleneck." },
      { goalId: "muscle_growth", framing: "Lean mass directly determines work capacity in CrossFit; modest hypertrophic support has practical performance value." },
    ],
    whyDifferent: {
      intro: "No other sport asks athletes to maintain Olympic-lifting strength, gymnastics flexibility, and 2-mile-run endurance simultaneously. The recovery demand is unique.",
      points: [
        "Shoulder, lower back, and knee injuries dominate CrossFit injury data — the same tissues BPC-157 has the strongest evidence for.",
        "Programming variability means consistent muscle protein synthesis support is harder than in single-modality training.",
        "Open and Games competition cycles compress recovery windows below what training volume requires.",
      ],
    },
    bodySections: [
      {
        id: "open-prep",
        eyebrow: "Competition timing",
        title: "Cycling around the Open and Games",
        paragraphs: [
          "If you compete at sanctioned events, plan your compound use around the testing window. The Open is generally not tested at the recreational level; the Games and Semifinals are. Recovery and sleep compounds with no WADA designation are the safer choices for tested phases.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "What peptides actually do for CrossFitters",
        paragraphs: [
          "CrossFit's recovery bill is the sport's defining feature — high volume across mixed modalities, frequent eccentric loading, and minimal off-season. Peptides earn a place where recovery markers consistently fail despite dialed-in sleep, nutrition, and programming. They are not a substitute for periodization or for taking a recovery week.",
        ],
        bullets: [
          "Persistent shoulder, elbow, knee, or hip irritation that has resisted 4+ weeks of standard mobility work — BPC-157 has the cleanest case.",
          "Recovery markers (sleep, HRV, training tolerance) trending poorly across a heavy block — short GH-secretagogue support.",
          "Sleep architecture failures with high training volume — sleep-supporting peptides have a case once lifestyle is dialed.",
          "Performance-enhancement use is prohibited in sanctioned events at the Games / Semifinals level — verify before any compound.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline against a year-round demand",
        paragraphs: [
          "CrossFit lacks a clear off-season, which means protocols that work for season-driven athletes (runners, fighters) need adaptation. The defining rule: build recovery weeks into programming and let peptide blocks ride those — not the other way around. Volume that requires compounds to survive is volume that needs to come down.",
        ],
        bullets: [
          "Test status matters at Open → Quarterfinals → Semifinals → Games progression — verify with the current CrossFit rulebook.",
          "BPC-157 cycles synced to highest-volume blocks; discontinue before any sanctioned tested event.",
          "Sleep-supporting compounds run during recovery weeks, not heavy blocks.",
          "Bloodwork (CBC, CMP, lipid, HCT, IGF-1) before and after any GH-axis cycle.",
        ],
      },
      {
        id: "movement-first",
        eyebrow: "Before peptides",
        title: "What movement modifications do that peptides cannot",
        paragraphs: [
          "Most CrossFit injuries have a movement-pattern explanation that peptides will not fix. Kipping pull-ups with poor shoulder mechanics, kettlebell snatches with collapsing posture, butterfly chest-to-bar at scaled fitness — these create the recurring irritations that no compound prevents. Fix the pattern first; peptides accelerate recovery from the load, not from bad load.",
        ],
        bullets: [
          "Replace kipping with strict variations during any current shoulder or elbow irritation.",
          "Address single-side dominance (uneven snatch / clean / push) before increasing volume.",
          "Programming that includes a true deload every 4–6 weeks outperforms any peptide.",
          "Sleep, eat enough carbohydrate, and respect rest days — recovery starts there.",
        ],
      },
    ],
    faqs: [
      {
        question: "Is BPC-157 banned in CrossFit?",
        answer: "BPC-157 is not explicitly on the CrossFit-adopted WADA prohibited list as of 2026, but may fall under general 'S0 — non-approved substances' prohibitions. Treat its status as unclear and discontinue well before any tested event.",
      },
      {
        question: "Will peptides help with shoulder pain from kipping?",
        answer: "BPC-157 has the strongest rotator cuff repair evidence of any research peptide. Combine with movement-modification (replace kipping with strict where pain occurs) and rotator cuff strengthening — peptides accelerate but don't replace rehab.",
      },
      {
        question: "Can I take peptides during the Open?",
        answer: "If you are at any chance of being selected for Semifinals or Games testing, do not use any peptide that's not specifically cleared. For most recreational athletes the Open is untested, but err on the side of caution if you have competitive aspirations.",
      },
    ],
    siblings: [
      { slug: "bodybuilders", title: "Peptides for Bodybuilders", audience: "Bodybuilders" },
      { slug: "natural-bodybuilders", title: "Peptides for Natural Bodybuilders", audience: "Natural BBers" },
      { slug: "runners", title: "Peptides for Runners", audience: "Runners" },
      { slug: "mma-fighters", title: "Peptides for MMA Fighters", audience: "MMA fighters" },
    ],
    relatedGoalIds: ["recovery", "muscle_growth"],
  },

  {
    id: "mma-fighters",
    slug: "mma-fighters",
    cluster: "athlete",
    audience: "MMA fighters",
    audienceChips: ["Combat sport", "Weight cuts", "TBI risk"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for MMA Fighters (2026)",
    seoDescription:
      "Three compounds for MMA: tissue recovery, neuroprotection for cumulative head impact, and sleep architecture support. USADA-aware.",
    h1: "Peptides for MMA Fighters",
    canonicalPath: "/blog/peptides-for/mma-fighters",
    primaryKeyword: "peptides for mma fighters",
    heroEyebrow: "Athlete · Combat sport",
    heroSummary:
      "MMA's recovery demand spans soft tissue, brain, and sleep. Three compounds address the most damaging chronic exposures of the sport.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "MMA combines high-volume soft-tissue load, cumulative head impact, and severe weight cuts. BPC-157 for tissue, a neuroprotective compound for cognitive resilience, and a sleep-supporting peptide form the three-front protocol — with USADA constraints front-loaded.",
    safetyFlags: [
      {
        label: "USADA tested at the UFC level",
        detail: "Most growth-related compounds will end a career. The protocol is constrained — confirm with your team's compliance lead.",
        severity: "danger",
      },
      {
        label: "Weight cuts amplify side effects",
        detail: "Dehydration interacts with most compounds. Time use to outside the cut window.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "recovery", framing: "Sparring and rolling volume produces soft-tissue damage that accumulates faster than most sports — BPC-157 is the dominant tested-status-clean recovery compound." },
      { goalId: "cognitive", framing: "Cumulative head impact in MMA carries long-term cognitive risk; neurotrophic compounds may support resilience between camps." },
      { goalId: "sleep", framing: "Camp-induced sleep deprivation compounds every other deficit — sleep architecture support is the single highest-leverage recovery intervention." },
    ],
    whyDifferent: {
      intro: "MMA's recovery problem is unlike any other sport. You are repairing soft tissue, brain, and sleep simultaneously, with weight cuts compounding all three.",
      points: [
        "Soft-tissue damage from striking and grappling exceeds what most non-combat athletes face in a year, compressed into a 6-week camp.",
        "Subconcussive head impact accumulates across years — neurotrophic compound use becomes a long-horizon decision, not just a recovery one.",
        "Weight cuts disrupt sleep, cortisol, and glucose regulation for weeks after the fight — recovery extends well past fight night.",
      ],
    },
    bodySections: [
      {
        id: "usada-context",
        eyebrow: "Testing context",
        title: "USADA changed the protocol math",
        paragraphs: [
          "The UFC's USADA program (2015–2023) and its successor testing protocol made traditional 'PED-adjacent' peptide use career-ending. Modern fighter protocols emphasize compounds with no listed WADA designation: BPC-157 (gray-zone), DSIP and Selank (not listed), and neuroprotective compounds like semax and cerebrolysin (not on standard panels).",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "What peptides actually do for fighters",
        paragraphs: [
          "MMA's recovery demand is the highest of any common sport — soft tissue, brain, sleep, and weight cuts all hit at once. Peptides earn a place when post-camp soft-tissue recovery has stalled, when neuroprotective compounds are layered into a career plan, or when sleep architecture has not recovered between camps. They are layered onto fight-camp programming, not in place of it.",
        ],
        bullets: [
          "Documented soft-tissue injury between camps that has not progressed in standard rehab — BPC-157 with clinician sign-off.",
          "Cumulative subconcussive impact concerns — neurotrophic compounds (semax, cerebrolysin) are a long-horizon discussion with neurology.",
          "Sleep failure persisting into and out of weight cuts — DSIP-class compounds have a case once recovery basics are dialed.",
          "Performance enhancement is prohibited in every sanctioned promotion — verify each compound before any cycle.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline around camp and cut",
        paragraphs: [
          "Fighter protocols are structured around camp cycles, not around steady-state training. The same compound that is reasonable during camp recovery is risky into a weigh-in. Out-of-competition testing, fight-night testing, and weight-cut interactions all change which compounds belong in the rotation.",
        ],
        bullets: [
          "Verify every compound against the current USADA / promotion testing list — interpretations shift annually.",
          "Discontinue compounds with detectable metabolites at least 8–12 weeks before any tested fight.",
          "Avoid GH-axis stacking during weight cuts — interacts with already-stressed glucose and electrolyte regulation.",
          "Coordinate every compound with a doctor familiar with combat athletes — bloodwork after every camp.",
        ],
      },
      {
        id: "tbi-context",
        eyebrow: "Brain priority",
        title: "Why brain protocols are a career-long decision",
        paragraphs: [
          "Subconcussive head impact is the longest-arc risk in MMA — and the one that is hardest to undo. Neurotrophic compound use should be framed as career-long, not camp-specific. The decision is best made with a neurologist familiar with TBI and combat sports, and it should sit alongside training-modification choices (sparring volume, headgear, heavy-bag work).",
        ],
        bullets: [
          "Cumulative impact, not single concussions, drives long-term risk — the protocol is preventative, not reactive.",
          "Neurotrophic compounds (semax, cerebrolysin, dihexa) have plausible mechanisms; long-term human data is limited.",
          "Sparring volume and intensity are the dominant input — modify training, not just supplement.",
          "Coordinate any neurotrophic protocol with a neurology consult; this is not solo-experimentation territory.",
        ],
      },
    ],
    faqs: [
      {
        question: "Are sleep peptides banned in MMA?",
        answer: "DSIP, epitalon, and Selank are not specifically listed on the WADA prohibited list as of 2026. They may fall under general 'S0' provisions in some interpretations. Verify with your team's testing-compliance lead before use.",
      },
      {
        question: "Will cerebrolysin help with CTE risk?",
        answer: "Cerebrolysin has clinical use in traumatic brain injury recovery in some countries. Whether it modifies long-term CTE risk in fighters with cumulative subconcussive impact is unproven. The mechanistic case is plausible; the human longitudinal evidence does not yet exist.",
      },
      {
        question: "Can I use BPC-157 during a fight camp?",
        answer: "Many fighters do, on the basis that BPC-157 is not specifically named on the WADA list. However, it may fall under 'S0 — non-approved substances' depending on testing interpretation. Risk-tolerance and federation guidance should drive the decision.",
      },
    ],
    siblings: [
      { slug: "bodybuilders", title: "Peptides for Bodybuilders", audience: "Bodybuilders" },
      { slug: "crossfitters", title: "Peptides for CrossFitters", audience: "CrossFitters" },
      { slug: "runners", title: "Peptides for Runners", audience: "Runners" },
    ],
    relatedGoalIds: ["recovery", "cognitive", "sleep"],
  },

  // ──────────────────────────────────────────────────────────────────
  // AESTHETIC
  // ──────────────────────────────────────────────────────────────────
  {
    id: "looksmaxxing",
    slug: "looksmaxxing",
    cluster: "aesthetic",
    audience: "Looksmaxxers",
    audienceChips: ["Aesthetic", "Skin", "Recomp"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Looksmaxxing (2026)",
    seoDescription:
      "Three compounds for looksmaxxing: skin and collagen, muscle support, and fat loss. The aesthetic-focused peptide protocol that actually works.",
    h1: "Peptides for Looksmaxxing",
    canonicalPath: "/blog/peptides-for/looksmaxxing",
    primaryKeyword: "peptides for looksmaxxing",
    heroEyebrow: "Aesthetic",
    heroSummary:
      "Looksmaxxing intersects skin, muscle, and body fat. Three compounds match those three levers — and skip the rest of the noise.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Looksmaxxing — the broad pursuit of aesthetic optimization — maps to three physiological levers: skin quality, lean mass, and body fat. GHK-Cu for skin, a growth-factor or GH-axis compound for muscle, and an incretin-class compound for fat loss is the focused three-compound protocol.",
    safetyFlags: [
      {
        label: "Avoid Melanotan II for tanning",
        detail: "Melanotan II affects pigmentation in ways that complicate melanoma screening and has unpredictable side effects.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "skin_hair", framing: "Skin quality is the single most visible aesthetic variable — GHK-Cu has direct mechanism and the cleanest cosmetic evidence." },
      { goalId: "muscle_growth", framing: "Lean mass drives both shape and the visible 'jawline tension' that looksmaxxing communities prioritize." },
      { goalId: "fat_loss", framing: "Body fat percentage is the dominant variable for visible musculature and facial definition." },
    ],
    whyDifferent: {
      intro: "The aesthetic upside is real, but most of the looksmaxxing peptide discourse oversells dramatic compounds and underrates the basics.",
      points: [
        "Skin texture, evenness, and elasticity are achievable with topical GHK-Cu over months — not weeks, and not via injection alone.",
        "Lean mass changes show on the face (temple fullness, jawline definition) within 12–16 weeks of consistent resistance training and adequate protein.",
        "Body fat below ~12% in men and ~20% in women produces visible facial definition; chasing lower than that has diminishing aesthetic returns.",
      ],
    },
    bodySections: [
      {
        id: "skip-melanotan",
        eyebrow: "Skip list",
        title: "Why Melanotan II isn't on the list",
        paragraphs: [
          "Melanotan II is the obvious looksmaxxing compound — it tans skin without sun exposure. The reasons to skip it: unpredictable mole darkening complicates melanoma screening, nausea and flushing are common, and the pigmentation effects are uneven. The aesthetic case is real; the risk-reward is not favorable.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "What peptides realistically change",
        paragraphs: [
          "Looksmaxxing protocols overestimate what compounds change and underestimate what training, sleep, diet, skincare, and dental work change. Peptides have a real role in skin quality and recovery — neither of which is the dominant looksmaxxing variable. Set the expectation correctly: peptides are a multiplier on the lifestyle inputs, not a substitute for them.",
        ],
        bullets: [
          "Skin texture, fine lines, post-acne scarring — topical GHK-Cu has a direct mechanism with the lowest systemic exposure.",
          "Hair density and shedding — topical GHK-Cu and conservative copper-peptide protocols; address scalp environment, not just compound.",
          "Body composition during a cut — incretin-class compounds for stubborn fat, GH support for lean mass preservation, clinician-led.",
          "Bone structure (jawline, brow, cheek) does not change with peptides — surgical and orthodontic levers only.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline around realistic expectations",
        paragraphs: [
          "Aesthetic protocols fail most often from impatience. Skin remodeling runs in months, not weeks; hair changes take six months to read; body composition reflects total energy balance more than any compound. Track photos at standardized lighting and time of day, and judge protocols on 90+ day timelines.",
        ],
        bullets: [
          "Standardized photos (same lighting, time, pose) at baseline and every 30 days — your mirror is unreliable.",
          "Topical-first where the indication is local — lower systemic exposure, easier to cycle.",
          "Cycle compounds with stop dates — open-ended use makes side effects harder to attribute.",
          "Bloodwork before and after any systemic protocol — bring data to your clinician.",
        ],
      },
      {
        id: "what-actually-matters",
        eyebrow: "Order of operations",
        title: "Where to spend energy before any compound",
        paragraphs: [
          "Most aesthetic gains come from inputs that have nothing to do with peptides: sleep quality and quantity, body composition, skin protection, dental health, and grooming. Compounds layered on top of dialed-in lifestyle inputs return modestly; compounds layered on top of poor lifestyle inputs return almost nothing.",
        ],
        bullets: [
          "Sleep — the single highest-leverage aesthetic input; chronic poor sleep shows on the face directly.",
          "Sun protection (SPF, hat, smart exposure) outperforms every anti-aging peptide.",
          "Dental work (orthodontics, whitening, retainers) often delivers more visible change than any cosmetic compound.",
          "Body composition — visible aesthetic outcomes depend on body fat and lean mass first, compounds second.",
        ],
      },
    ],
    faqs: [
      {
        question: "What is the best peptide for jawline definition?",
        answer: "There is no peptide that directly changes bone structure. Jawline definition comes from lean mass on the face and lower body fat. The closest peptide mechanism is the combination of muscle support compounds and fat loss compounds — but mewing and orthognathic surgery are the only direct levers for bone-driven jawline.",
      },
      {
        question: "Will GHK-Cu work topically?",
        answer: "Yes. GHK-Cu has the most cosmetic evidence as a topical compound for skin elasticity, fine lines, and dermal repair. Injection is also used but topical is the dominant cosmetic application. Expect modest, gradual improvement over 8–12 weeks of consistent use.",
      },
      {
        question: "Is Melanotan II safe?",
        answer: "Side effects include nausea, flushing, and unpredictable changes to existing moles. Pigmentation effects are uneven and complicate dermatologic screening for melanoma. The risk-reward is unfavorable for cosmetic tanning.",
      },
    ],
    siblings: [
      { slug: "bodybuilders", title: "Peptides for Bodybuilders", audience: "Bodybuilders" },
      { slug: "men-in-their-20s", title: "Peptides for Men in Their 20s", audience: "Men 20–29" },
      { slug: "men-in-their-30s", title: "Peptides for Men in Their 30s", audience: "Men 30–39" },
      { slug: "women-in-their-20s", title: "Peptides for Women in Their 20s", audience: "Women 20–29" },
    ],
    relatedGoalIds: ["skin_hair", "muscle_growth", "fat_loss"],
  },

  // ──────────────────────────────────────────────────────────────────
  // LIFESTYLE
  // ──────────────────────────────────────────────────────────────────
  {
    id: "students",
    slug: "students",
    cluster: "lifestyle",
    audience: "Students",
    audienceChips: ["Cognitive", "Sleep-debt", "Sedentary"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Students (2026)",
    seoDescription:
      "Two compounds for students: cognitive support during exam periods and metabolic support against academic-lifestyle weight gain.",
    h1: "Peptides for Students",
    canonicalPath: "/blog/peptides-for/students",
    primaryKeyword: "peptides for students",
    heroEyebrow: "Lifestyle · Student",
    heroSummary:
      "Student life means sustained cognitive load and sedentary creep. Two compounds — cognition and metabolic support — address the dominant pressures.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 7,
    tldr: "Students face sustained cognitive demand and sedentary lifestyle drift simultaneously. Semax or Selank for focus and stress modulation, paired with a fat-loss compound where indicated, addresses the dominant pressures without amphetamine-class side effects.",
    safetyFlags: [
      {
        label: "Sleep is more important than any peptide",
        detail: "No compound substitutes for 7+ hours of sleep. Address sleep first, then consider cognitive support.",
        severity: "info",
      },
    ],
    priorityGoals: [
      { goalId: "cognitive", framing: "Semax and related compounds have human cognitive data without the dependence or comedown profile of stimulants." },
      { goalId: "fat_loss", framing: "The freshman 15 is a real metabolic shift — sedentary lifestyle plus increased eating produces visible weight gain that becomes harder to reverse over years." },
    ],
    whyDifferent: {
      intro: "Students are young, hormonally intact, and time-constrained. The compounds with real cases are narrow — focus and metabolism, not muscle or libido.",
      points: [
        "Cognitive peptides (semax, selank) have human data for focus, working memory, and stress modulation without amphetamine-class side effects.",
        "Sedentary lifestyle drift during exam-heavy periods produces real metabolic shifts — cortisol, sleep, and weight all suffer.",
        "Most peptides marketed to young people target problems they don't have. Skip the muscle and libido stacks.",
      ],
    },
    bodySections: [
      {
        id: "fix-sleep-first",
        eyebrow: "Foundation",
        title: "Sleep is the cognitive enhancer that actually works",
        paragraphs: [
          "Before any compound, fix sleep. A consistent bedtime, a cool dark room, and no caffeine after 2 PM produce more cognitive gains than any peptide. If you cannot sustain 7+ hours of sleep, no compound will outperform sleep-deprived baseline reliably.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "What actually justifies a protocol as a student",
        paragraphs: [
          "Most students researching peptides are looking for an academic-performance shortcut. The honest answer is that peptides are weaker performance enhancers than sleep, structured study, and daily walking. The narrow cases where compounds belong: acute anxiety unresponsive to lifestyle, persistent sleep issues with documented hygiene work, and post-injury recovery that has stalled.",
        ],
        bullets: [
          "Anxiety persisting through dialed-in sleep and lifestyle work — Selank has anxiolytic data without dependence profile of benzodiazepines.",
          "Sleep failure (initiation or maintenance) despite consistent schedule and good hygiene — sleep-supporting peptides have a case.",
          "Soft-tissue injury (sports, repetitive strain) stalled past standard rehab — BPC-157.",
          "Performance enhancement (focus, energy, exam stamina) is not the case — fix sleep, eating cadence, and study structure first.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline in the most variable life stage",
        paragraphs: [
          "Student life is the most variable input pattern of any adult demographic — semesters, breaks, exam periods, social schedules. Compound use during exam periods is risky precisely because the baseline is already unstable. Run short cycles during the steadier weeks; avoid initiating any new compound during finals or major life transitions.",
        ],
        bullets: [
          "Do not start any new compound during finals, midterms, or major schedule changes.",
          "Use campus medical services if there's any clinical question — student health centers exist for exactly this.",
          "Cycle compounds against the semester calendar — start and stop dates well clear of high-stakes weeks.",
          "Bloodwork (basic CBC, CMP, lipid) before starting anything systemic.",
        ],
      },
      {
        id: "post-graduation-context",
        eyebrow: "What changes after graduation",
        title: "Where the protocol stabilizes",
        paragraphs: [
          "Post-graduation life patterns are more stable: regular sleep is achievable, exercise becomes consistent, and the variability of college fades. The protocol that earned a place during school often does not earn the same place after. Re-evaluate each compound annually against the new baseline.",
        ],
        bullets: [
          "Sleep regularity post-graduation is the single biggest variable change — re-evaluate sleep-supporting compounds.",
          "Health insurance access changes — coordinate with primary care.",
          "Bloodwork cadence at least annually as adult patterns set in.",
        ],
      },
    ],
    faqs: [
      {
        question: "Are nootropic peptides better than Adderall?",
        answer: "Different profiles. Adderall increases dopamine and norepinephrine acutely — strong stimulant effect with comedown, dependence, and prescription requirement. Semax and Selank work via different mechanisms (BDNF, GABA) with no euphoria, no comedown, and milder subjective effect.",
      },
      {
        question: "Will peptides help with exam-period weight gain?",
        answer: "A GLP-1 is overkill for typical student weight gain. The lifestyle changes (consistent eating schedule, resistance training 2× per week, walking after meals) produce more sustainable results without the cost or side effects.",
      },
      {
        question: "Are nootropic peptides addictive?",
        answer: "Semax and Selank do not have a known dependence profile. They are not controlled substances. Whether they are 'safe' for chronic use remains under-studied; cycling (5 days on, 2 off, or 4 weeks on, 1 off) is the conservative pattern.",
      },
    ],
    siblings: [
      { slug: "men-in-their-20s", title: "Peptides for Men in Their 20s", audience: "Men 20–29" },
      { slug: "women-in-their-20s", title: "Peptides for Women in Their 20s", audience: "Women 20–29" },
      { slug: "entrepreneurs", title: "Peptides for Entrepreneurs", audience: "Entrepreneurs" },
      { slug: "shift-workers", title: "Peptides for Shift Workers", audience: "Shift workers" },
    ],
    relatedGoalIds: ["cognitive", "fat_loss"],
  },

  {
    id: "entrepreneurs",
    slug: "entrepreneurs",
    cluster: "lifestyle",
    audience: "Entrepreneurs",
    audienceChips: ["High cognitive load", "Stress", "Sleep-debt"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Entrepreneurs (2026)",
    seoDescription:
      "Three compounds for founders and executives: cognitive support, sleep architecture, and anxiety modulation. Built for sustained mental load.",
    h1: "Peptides for Entrepreneurs",
    canonicalPath: "/blog/peptides-for/entrepreneurs",
    primaryKeyword: "peptides for entrepreneurs",
    heroEyebrow: "Lifestyle · Founder",
    heroSummary:
      "Founders trade sleep, stable mood, and cognitive reserve for company runway. Three compounds address the dominant trade-offs without amphetamine-class cost.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Entrepreneurs face sustained cognitive demand, chronic sleep debt, and elevated baseline anxiety simultaneously. Semax for focus, a sleep-architecture peptide for the limited rest available, and Selank for stress modulation form the three-front cognitive protocol.",
    safetyFlags: [
      {
        label: "Compounds don't substitute for boundaries",
        detail: "If you are running on under 6 hours of sleep regularly, no peptide will sustain peak cognitive performance.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "cognitive", framing: "Sustained executive function over months — not minutes — is what founders need; semax has the cleanest evidence for this profile." },
      { goalId: "sleep", framing: "Limited sleep is the founder reality; making the 5–6 hours you do get higher-quality is the only realistic lever." },
      { goalId: "anxiety", framing: "Baseline anxiety in founder populations runs higher than in any non-clinical group; Selank reduces it without sedation." },
    ],
    whyDifferent: {
      intro: "Founder physiology runs hotter than most adult populations. The cognitive and stress load is real, persistent, and damaging.",
      points: [
        "Cortisol patterns in founder populations show chronic elevation that mirrors clinical stress states.",
        "Sleep restriction is structural — peptides that improve sleep quality matter more than total-hours interventions.",
        "Anxiety frequently presents as 'productive worry' that masks the metabolic and cognitive cost.",
      ],
    },
    bodySections: [
      {
        id: "sustainability",
        eyebrow: "Sustainability",
        title: "Compounds are a stopgap, not a substitute",
        paragraphs: [
          "Every founder protocol eventually fails if the lifestyle does. Peptides extend the runway of sustained high performance; they do not create new runway. Pair any compound use with deliberate sleep, exercise, and stress-management practice — otherwise the compounds carry the system, and that is not a stable equilibrium.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "Indications that justify a compound at founder pace",
        paragraphs: [
          "Founder protocols fail when compounds are treated as productivity tools rather than as adjuncts to a disciplined lifestyle. The cases that justify peptides are narrow: sleep architecture failure where lifestyle inputs are dialed, chronic anxiety unresponsive to baseline work, recovery deficits from extended cognitive and physical demand, and the eventual cardiovascular markers that come with sustained stress.",
        ],
        bullets: [
          "Sleep failure (initiation or maintenance) despite consistent schedule, dark cool room, and disciplined caffeine timing — DSIP-class compounds have a case.",
          "Persistent anxiety unresponsive to lifestyle work — Selank has anxiolytic data without dependence profile of benzodiazepines.",
          "Recovery deficits (HRV, resting HR, training tolerance) from chronic high-stress periods — short BPC-157 or GH-secretagogue blocks.",
          "Visceral fat accumulation and cardiovascular markers shifting under chronic stress — coordinate with primary care; GLP-1s may enter the picture.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline through travel and irregular schedules",
        paragraphs: [
          "Founder schedules break protocol discipline the way nothing else does. Cross-timezone travel, irregular meals, missed workouts, and 80-hour weeks all degrade the inputs that any compound depends on. Design protocols that survive the volatility — short cycles, low compound counts, frequent labwork.",
        ],
        bullets: [
          "Schedule compound cycles around stable life stretches, not crunch periods.",
          "Maintain bloodwork cadence quarterly — annual misses the changes that founder schedules cause.",
          "Travel-aware: melatonin and sleep-supporting compounds become high-leverage during chronic timezone shifts.",
          "Disclose every compound to your primary care or executive physical clinician — the silent risk is interaction with antihypertensives, sleep medications, or psychiatric medications.",
        ],
      },
      {
        id: "long-arc",
        eyebrow: "The longer the runway",
        title: "What the protocol looks like at year 5",
        paragraphs: [
          "Founder careers run for years; the protocols that hold up over that arc are simpler, more clinical, and more lifestyle-anchored than the ones that look good in year one. By year five the compounds that remain are typically a sleep-supporting peptide and BPC-157 cycles when training load demands — everything else gets pruned as data accumulates.",
        ],
        bullets: [
          "Simplify over time — protocols that grow are protocols that haven't been audited.",
          "Annual clinician check-in becomes biannual or quarterly as cardiovascular and metabolic markers shift.",
          "Sleep, training, and stress-management protocols outlast every compound rotation.",
        ],
      },
    ],
    faqs: [
      {
        question: "Will peptides replace my morning stimulant routine?",
        answer: "Probably not completely. Semax and Selank produce milder cognitive effects than caffeine or amphetamines. Many founders use them alongside, not instead of, their existing stimulant routine — for sustained focus rather than acute alertness.",
      },
      {
        question: "Are these compounds drug-tested at executive physicals?",
        answer: "Standard executive physicals do not include peptide panels. Most research peptides have no widely-deployed urine or blood tests. Disclose all compounds to your physician anyway — interactions matter.",
      },
      {
        question: "Can I use these long-term?",
        answer: "Most cognitive peptides are cycled (5 days on, 2 off, or 4 weeks on, 1 off) rather than run continuously. Long-term continuous use of any single compound has limited human data — cycling is the conservative pattern.",
      },
    ],
    siblings: [
      { slug: "students", title: "Peptides for Students", audience: "Students" },
      { slug: "shift-workers", title: "Peptides for Shift Workers", audience: "Shift workers" },
      { slug: "biohackers", title: "Peptides for Biohackers", audience: "Biohackers" },
      { slug: "men-over-40", title: "Peptides for Men Over 40", audience: "Men 40–49" },
    ],
    relatedGoalIds: ["cognitive", "sleep", "anxiety"],
  },

  {
    id: "shift-workers",
    slug: "shift-workers",
    cluster: "lifestyle",
    audience: "Shift workers",
    audienceChips: ["Circadian disruption", "Immune stress", "Cognitive load"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Shift Workers (2026)",
    seoDescription:
      "Three compounds for shift workers: sleep architecture, immune support, and cognitive resilience. Built for chronic circadian disruption.",
    h1: "Peptides for Shift Workers",
    canonicalPath: "/blog/peptides-for/shift-workers",
    primaryKeyword: "peptides for shift workers",
    heroEyebrow: "Lifestyle · Shift work",
    heroSummary:
      "Rotating shifts and night work damage sleep, immunity, and cognition together. Three compounds address each axis of the circadian cost.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Shift work is classified as a probable carcinogen by the IARC, primarily due to chronic circadian disruption. Sleep-architecture support, immune-supporting peptides, and cognitive compounds for night-shift performance form a three-front protocol against the dominant biological costs.",
    safetyFlags: [
      {
        label: "Address shift pattern if possible",
        detail: "Forward-rotating shifts (day → evening → night) are biologically less damaging than backward-rotating ones.",
        severity: "info",
      },
    ],
    priorityGoals: [
      { goalId: "sleep", framing: "Daytime sleep is structurally lower quality than nighttime sleep — compounds that improve sleep architecture matter more here than in any other population." },
      { goalId: "immune", framing: "Chronic circadian disruption suppresses immune function measurably; thymic peptides have direct mechanism." },
      { goalId: "cognitive", framing: "Cognitive performance crashes between 3 and 6 AM regardless of sleep; targeted compounds can blunt the dip." },
    ],
    whyDifferent: {
      intro: "Shift work imposes biological costs that no amount of willpower fixes. The protocol assumes the disruption is permanent and addresses the downstream damage.",
      points: [
        "Night shift workers have measurably higher rates of cardiovascular disease, type 2 diabetes, and several cancers — circadian disruption is the proposed mechanism.",
        "Daytime sleep produces less slow-wave sleep and REM than nighttime sleep at the same total duration.",
        "Cognitive performance on the night shift drops by 20–40% between 3 and 6 AM regardless of total sleep.",
      ],
    },
    bodySections: [
      {
        id: "light-strategy",
        eyebrow: "Light timing",
        title: "Light timing is as important as any compound",
        paragraphs: [
          "Bright light during the night shift (especially the first half) suppresses melatonin and supports alertness. Strict light avoidance during the morning commute home preserves sleep ability. Sunglasses on the drive home are a free intervention that outperforms most compounds.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "Indications shaped by circadian disruption",
        paragraphs: [
          "Shift work is a chronic stressor on three axes simultaneously — sleep, immunity, and metabolic health. Peptides earn a place where the compound directly addresses one of those axes and the disruption is unavoidable (true rotating or permanent night shifts, not just inconsistent sleep). The honest hierarchy: light strategy first, sleep-supporting peptides second, immune and metabolic support layered on chronic-exposure timelines.",
        ],
        bullets: [
          "Sleep failure during daytime sleep windows despite blackout, cool room, and disciplined wind-down — DSIP-class compounds have a case.",
          "Recurring infections or chronically low immune markers — thymic-support peptides have plausible mechanism.",
          "Visceral fat accumulation and metabolic shifts that track shift-work exposure — coordinate with primary care; GLP-1s if indicated.",
          "Cognitive complaints during night shifts — Selank or semax may help acutely; sleep optimization helps more.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline against rotating schedules",
        paragraphs: [
          "Shift-work protocols depend on whether the shift is fixed or rotating. Fixed nights are a stable adaptation target; rotating shifts are a chronic disruption pattern that no compound fully solves. Sync cycles to the most stable stretches available and avoid initiating new compounds during a shift rotation.",
        ],
        bullets: [
          "Identify the most stable schedule stretch and run cycles during it — not during rotation weeks.",
          "Bloodwork every 6 months — shift workers show metabolic and inflammatory marker shifts faster than the general population.",
          "Coordinate with primary care about cardiovascular and metabolic monitoring; shift work is an independent risk factor.",
          "Light, food timing, and consistent sleep windows outperform every compound — establish those before adding peptides.",
        ],
      },
      {
        id: "long-arc",
        eyebrow: "Long-term context",
        title: "What changes after years of shift work",
        paragraphs: [
          "Years of shift work create cumulative cardiometabolic risk that no single protocol fully reverses. The long-arc plan: minimize shift-work exposure where possible, schedule periodic recovery stretches, and run aggressive cardiometabolic monitoring. Peptides are tactical layers; the strategic decision is whether the schedule itself is sustainable.",
        ],
        bullets: [
          "Annual full cardiometabolic workup at minimum; biannual after 5+ years of shift work.",
          "Treat each new symptom as potentially shift-related — fatigue, weight gain, mood shifts, GI complaints.",
          "Plan deliberate recovery stretches (multi-week schedule normalization) periodically.",
          "If the schedule is not sustainable, the protocol decision is upstream of any compound.",
        ],
      },
    ],
    faqs: [
      {
        question: "Will DSIP help me sleep during the day?",
        answer: "DSIP has limited but suggestive human data for sleep architecture, including some daytime-sleep contexts. It is not a sedative — expect modest improvement in sleep depth rather than dramatic onset effect.",
      },
      {
        question: "How do I protect my immune system on rotating shifts?",
        answer: "Thymic peptides (thymosin alpha-1) have human data for immune resilience. Equally important: vitamin D sufficiency, adequate protein intake, and minimizing alcohol — which compounds circadian damage.",
      },
      {
        question: "Are cognitive peptides safe for night shifts?",
        answer: "Semax and similar compounds have not been studied specifically in night-shift contexts. They lack the cardiac stimulant effects of modafinil or amphetamines and are unlikely to cause acute problems, but long-term shift-work cognitive support is an under-studied area.",
      },
    ],
    siblings: [
      { slug: "military", title: "Peptides for Military", audience: "Active-duty military" },
      { slug: "entrepreneurs", title: "Peptides for Entrepreneurs", audience: "Entrepreneurs" },
      { slug: "students", title: "Peptides for Students", audience: "Students" },
    ],
    relatedGoalIds: ["sleep", "immune", "cognitive"],
  },

  {
    id: "military",
    slug: "military",
    cluster: "lifestyle",
    audience: "Active-duty military",
    audienceChips: ["High load", "Recovery-limited", "Tested"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Military (2026)",
    seoDescription:
      "Three compounds for active-duty service members: tissue recovery, cognitive resilience, and sleep architecture. DoD-aware selection.",
    h1: "Peptides for Active-Duty Military",
    canonicalPath: "/blog/peptides-for/military",
    primaryKeyword: "peptides for military",
    heroEyebrow: "Lifestyle · Military",
    heroSummary:
      "Military life combines high physical load, cognitive demand, and unpredictable sleep. Three compounds address the dominant recovery axes — within service-member compliance constraints.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "Active-duty service members face cumulative musculoskeletal injury, sustained cognitive demand, and irregular sleep simultaneously. BPC-157 for tissue, a cognitive peptide for sustained operations, and a sleep-supporting compound form the three-front protocol — with DoD compliance constraints front-loaded.",
    safetyFlags: [
      {
        label: "DoD policy on supplements is strict",
        detail: "Some peptides are prohibited regardless of WADA status. Verify with your command's medical liaison.",
        severity: "danger",
      },
      {
        label: "Disclose to medical at every appointment",
        detail: "Service members are obligated to disclose all non-prescribed compounds. Non-disclosure can have UCMJ implications.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "recovery", framing: "Musculoskeletal injury is the leading cause of medical separation from service — soft-tissue support has direct career-preserving value." },
      { goalId: "cognitive", framing: "Sustained operations and decision-fatigue scenarios benefit from cognitive compounds without amphetamine side effects." },
      { goalId: "sleep", framing: "Irregular sleep is structural in military life — improving the quality of available sleep matters more than total duration." },
    ],
    whyDifferent: {
      intro: "Service members face a combination of physical, cognitive, and sleep stressors unlike most civilian populations — with regulatory constraints unique to military service.",
      points: [
        "Musculoskeletal injuries drive the majority of medical discharges; recovery support has direct career impact.",
        "Sustained operations expose service members to cognitive loads that exceed civilian work-week patterns.",
        "DoD supplement policy and OPSS guidance restrict many compounds available to civilians.",
      ],
    },
    bodySections: [
      {
        id: "opss-compliance",
        eyebrow: "Compliance",
        title: "Check OPSS before any compound",
        paragraphs: [
          "Operation Supplement Safety (OPSS) maintains a list of prohibited and high-risk supplements. Many peptides fall into ambiguous categories. Verify with your unit medical liaison and your command's policy — non-disclosure carries UCMJ implications beyond civilian career consequences.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "What's available to active-duty service members",
        paragraphs: [
          "The candidate list for active-duty peptide use is narrow. Performance-enhancement compounds are off the table; most research peptides exist in regulatory gray zones that command policy may classify as prohibited. The cases that earn a careful, command-aware protocol are documented injury recovery and post-deployment sleep or anxiety issues where DoD medical channels have been engaged first.",
        ],
        bullets: [
          "Documented soft-tissue injury that has stalled in standard rehab — discuss BPC-157 with your unit medical provider; never run without disclosure.",
          "Post-deployment sleep and anxiety — DoD medical resources first; peptide adjuncts only with explicit clinician guidance.",
          "Cognitive performance or focus enhancement — off the table; performance enhancers carry UCMJ exposure.",
          "Body composition / weight cuts for tape — the discipline solution is nutritional and training, not pharmacological.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline at career-stakes scrutiny",
        paragraphs: [
          "Active-duty protocols carry consequences that civilian protocols do not. The dominant rule: every compound goes through command medical, every cycle is documented, and nothing rides on the assumption that 'gray zone' means 'safe.' Drug testing, fitness testing, and security clearance reviews all create exposure that the same compound would not create in civilian life.",
        ],
        bullets: [
          "Disclose every compound to your unit medical provider before starting — UCMJ exposure on non-disclosure exceeds civilian risk.",
          "Verify OPSS, current DoD instruction, and your command's specific policy — they evolve.",
          "Document everything: prescription, intent, supervising provider, dates, doses.",
          "Deployment, PCS, and operational tempo all change the protocol — re-verify policy at each transition.",
        ],
      },
      {
        id: "bridge-to-veterans",
        eyebrow: "After separation",
        title: "What changes when you leave the service",
        paragraphs: [
          "Separation opens up the protocol options considerably — but it also introduces the long-arc considerations that come with chronic exposures (heavy training loads, combat trauma, joint and back issues, sleep degradation). VA care coordination becomes the central variable, and the veterans page covers that protocol context.",
        ],
        bullets: [
          "VA care coordination becomes the foundation for any peptide protocol post-separation.",
          "Chronic exposures (joints, back, sleep, mood) often surface 12–24 months after separation.",
          "Compound list expands but the discipline (bloodwork, clinician coordination) does not relax.",
          "Read on after separation:",
        ],
      },
    ],
    faqs: [
      {
        question: "Are peptides prohibited by the DoD?",
        answer: "DoD policy on peptides is evolving and varies by service and command. Many compounds are not specifically listed but may fall under general supplement prohibitions. Check the Operation Supplement Safety database and consult your medical liaison before any use.",
      },
      {
        question: "Will peptides show up on a unit urinalysis?",
        answer: "Standard DoD urinalysis tests for controlled substances and metabolites — not peptides. However, some research peptides metabolize to controlled substance-adjacent compounds. Cleared use is not the same as undetectable use; non-disclosure carries career risk.",
      },
      {
        question: "Can BPC-157 help with rucking injuries?",
        answer: "BPC-157 has the strongest tendon and soft-tissue evidence of any research peptide, including for plantar fascia, Achilles, and lower back issues common in rucking-heavy roles. Pair with load management and rehab — peptides accelerate but don't replace those.",
      },
    ],
    siblings: [
      { slug: "veterans", title: "Peptides for Veterans", audience: "Veterans" },
      { slug: "shift-workers", title: "Peptides for Shift Workers", audience: "Shift workers" },
      { slug: "mma-fighters", title: "Peptides for MMA Fighters", audience: "MMA fighters" },
    ],
    relatedGoalIds: ["recovery", "cognitive", "sleep"],
  },

  {
    id: "veterans",
    slug: "veterans",
    cluster: "lifestyle",
    audience: "Veterans",
    audienceChips: ["Post-service", "Recovery", "Long-tail injury"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Veterans (2026)",
    seoDescription:
      "Three compounds for veterans: long-tail injury recovery, longevity support, and cognitive resilience. Built for post-service physical and cognitive load.",
    h1: "Peptides for Veterans",
    canonicalPath: "/blog/peptides-for/veterans",
    primaryKeyword: "peptides for veterans",
    heroEyebrow: "Lifestyle · Veterans",
    heroSummary:
      "Service leaves behind a recovery debt. Three compounds — tissue, longevity, cognitive — address the long-tail damage that surfaces years after separation.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 9,
    tldr: "Veterans face delayed-onset musculoskeletal pain, cumulative TBI effects, and accelerated aging signals from service-era stress. BPC-157 for unresolved injuries, a longevity compound for systemic support, and a neurotrophic peptide for cognitive resilience form a three-front protocol.",
    safetyFlags: [
      {
        label: "Coordinate with VA care",
        detail: "Your VA medical team should be informed of any compound use to coordinate with service-connected treatment.",
        severity: "warning",
      },
    ],
    priorityGoals: [
      { goalId: "recovery", framing: "Service-era injuries that healed incompletely often resurface as chronic pain decades later — soft-tissue support can address what surgery cannot." },
      { goalId: "anti_aging", framing: "Veteran populations show accelerated biological aging vs. age-matched civilian peers — system-support compounds address the gap." },
      { goalId: "cognitive", framing: "Cumulative TBI and blast exposure produce delayed cognitive effects; neurotrophic compounds may support resilience." },
    ],
    whyDifferent: {
      intro: "Veterans carry damage that often takes a decade to surface. The protocol logic emphasizes long-horizon repair and systemic support.",
      points: [
        "Service-connected musculoskeletal injuries often produce chronic pain syndromes that resist conventional treatment by separation.",
        "Veteran populations show accelerated biological aging on multiple markers vs. age-matched civilians.",
        "TBI exposure, including subconcussive events, has cumulative effects that emerge years after the inciting events.",
      ],
    },
    bodySections: [
      {
        id: "va-coordination",
        eyebrow: "VA coordination",
        title: "Tell your VA team",
        paragraphs: [
          "VA medical teams increasingly understand the peptide landscape but cannot coordinate care they don't know about. Disclose all compound use at your routine appointments and during any service-connected treatment review. Some compounds interact with medications commonly prescribed for service-related conditions.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "Indications shaped by service-connected exposure",
        paragraphs: [
          "Veteran protocols address a specific exposure profile: chronic joint and back load, cumulative TBI, sleep degradation, mental-health pressures, and accelerated biological aging. Peptides earn a place when they map to one of those exposures with a clinical endpoint, and when they sit alongside service-connected care rather than parallel to it.",
        ],
        bullets: [
          "Documented soft-tissue or joint dysfunction from service-connected wear — BPC-157 has the strongest case, coordinate with VA primary care.",
          "Cumulative TBI history — neurotrophic compounds (semax, cerebrolysin) are a long-arc decision with neurology, not a self-prescribed protocol.",
          "Sleep failure persisting through VA care — DSIP-class compounds may have a case once standard treatment has been engaged.",
          "Cardiometabolic shifts (visceral fat, lipid profile, glucose) — GLP-1s when indicated; some VAs prescribe.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Discipline alongside service-connected care",
        paragraphs: [
          "Veteran protocols must coexist with VA care and any concurrent specialty treatment. The dominant rule: every compound is disclosed at every appointment, interactions with VA-prescribed medications are mapped before each new addition, and concurrent mental-health treatment takes precedence over any cognitive or mood-related compound experimentation.",
        ],
        bullets: [
          "Disclose every peptide at routine VA visits and during any specialty consult.",
          "Map interactions with VA-prescribed medications (especially psychiatric, pain, and cardiovascular).",
          "Bloodwork quarterly during active protocols — VA can run most of the relevant panels.",
          "Mental-health care precedence: never substitute peptide adjuncts for PTSD or depression treatment.",
        ],
      },
      {
        id: "long-arc",
        eyebrow: "Long-arc context",
        title: "Aging with service-connected exposures",
        paragraphs: [
          "Veterans show accelerated biological aging across multiple markers; the protocols that hold up over decades are simpler and more clinical than the ones that look good in year one post-separation. Plan for protocol simplification over time, not expansion. The standing priorities are cardiometabolic monitoring, joint maintenance, sleep, and cognitive function.",
        ],
        bullets: [
          "Annual full cardiometabolic workup minimum; biannual once any marker shifts.",
          "Bone density baseline by age 50 — service-connected exposures often shift the timeline.",
          "Cognitive screening as part of routine care if TBI history is significant.",
          "Simplify the protocol as data accumulates — every compound that survives an annual review has earned it.",
        ],
      },
    ],
    faqs: [
      {
        question: "Will the VA prescribe peptides?",
        answer: "VA prescribing of research peptides is limited. Some VAs prescribe FDA-approved compounds (semaglutide, tirzepatide) for indicated conditions. Research peptides like BPC-157 are not typically VA-prescribed. Disclosure is still required regardless of source.",
      },
      {
        question: "Can peptides help with service-connected back pain?",
        answer: "BPC-157 has soft-tissue and disc-repair preclinical evidence, and many veterans use it for chronic lower-back issues. It does not replace physical therapy or, where indicated, surgical evaluation. Coordinate with your VA primary care team.",
      },
      {
        question: "Are neurotrophic peptides being studied for TBI?",
        answer: "Cerebrolysin has clinical use in TBI recovery in several countries (not FDA-approved in the US). Semax and similar compounds are under research for various cognitive applications. Human longitudinal data for late-effect TBI is limited.",
      },
    ],
    siblings: [
      { slug: "military", title: "Peptides for Military", audience: "Active-duty military" },
      { slug: "men-over-50", title: "Peptides for Men Over 50", audience: "Men 50–59" },
      { slug: "men-over-60", title: "Peptides for Men Over 60", audience: "Men 60+" },
      { slug: "biohackers", title: "Peptides for Biohackers", audience: "Biohackers" },
    ],
    relatedGoalIds: ["recovery", "anti_aging", "cognitive"],
  },

  {
    id: "biohackers",
    slug: "biohackers",
    cluster: "lifestyle",
    audience: "Biohackers",
    audienceChips: ["Longevity", "Self-tracking", "Experimentation"],
    ageRange: null,
    sex: "any",
    seoTitle: "Peptides for Biohackers (2026)",
    seoDescription:
      "Two compounds for biohackers: longevity-leaning systemic support and cognitive resilience. Data-first selection for self-tracking populations.",
    h1: "Peptides for Biohackers",
    canonicalPath: "/blog/peptides-for/biohackers",
    primaryKeyword: "peptides for biohackers",
    heroEyebrow: "Lifestyle · Biohacker",
    heroSummary:
      "Biohackers want healthspan extension with measurable inputs. Two compounds — longevity and cognitive — represent the highest-leverage interventions for a self-tracked population.",
    publishedAt: "2026-05-11",
    updatedAt: "2026-05-11",
    authorId: "research-desk",
    readMinutes: 8,
    tldr: "The biohacking population is self-tracking, data-literate, and seeks compounds with measurable biomarker effects. Longevity-leaning peptides (thymic, mitochondrial, senescence-modulating) and neurotrophic compounds for cognitive maintenance form the focused two-front protocol.",
    safetyFlags: [
      {
        label: "Track everything, change one thing at a time",
        detail: "Biomarker N-of-1 protocols only work when you isolate variables. Adding multiple compounds simultaneously destroys interpretability.",
        severity: "info",
      },
    ],
    priorityGoals: [
      { goalId: "anti_aging", framing: "Longevity-leaning compounds with biomarker-readable effects (epigenetic age, inflammatory markers) fit the biohacker measurement protocol." },
      { goalId: "cognitive", framing: "Cognitive resilience is the single most-tracked biohacker variable — and the one with the most actionable peptide options." },
    ],
    whyDifferent: {
      intro: "Biohackers don't need a beginner's guide. They need the compounds with the strongest measurable biomarker signal, in protocols that respect N-of-1 design.",
      points: [
        "Epigenetic age clocks, inflammation panels, and cognitive batteries can quantify peptide effects within a 12-week cycle.",
        "Most longevity peptides act in cycles, not continuously — this aligns naturally with on-off biomarker tracking.",
        "Cognitive testing (NIH Toolbox, dual N-back) gives objective endpoints for nootropic peptide protocols.",
      ],
    },
    bodySections: [
      {
        id: "n-of-1",
        eyebrow: "Protocol design",
        title: "How to run an N-of-1 on a peptide",
        paragraphs: [
          "Baseline labs and cognitive battery before starting. Single compound, single dose, fixed cycle length (typically 8–12 weeks). Repeat the same battery at end of cycle and after a 4-week washout. Compare to baseline. The discipline is in not adding a second variable until the first cycle is fully analyzed.",
        ],
      },
      {
        id: "decision-framework",
        eyebrow: "When peptides earn a place",
        title: "Compounds that fit a measurement-first protocol",
        paragraphs: [
          "Biohacker protocols are gated by measurable signal. Compounds with no biomarker readout, no plausible mechanism, or no human data do not belong in a measurement-first system regardless of community enthusiasm. The shortlist is the compounds where you can actually detect an effect within a single cycle — inflammation modulators, cognitive batteries, and a small set of GH-axis compounds with IGF-1 readouts.",
        ],
        bullets: [
          "Inflammatory markers (hs-CRP, IL-6, IL-10) — thymic and senescence-modulating peptides have plausible mechanisms.",
          "Cognitive battery (NIH Toolbox, dual N-back, sustained attention tests) — Selank, semax, and dihexa have measurable signal in many users.",
          "IGF-1 and sleep architecture (Oura, Whoop, PSG) — GH-axis compounds and DSIP show readable changes.",
          "Epigenetic age (Horvath, GrimAge) — long-cycle reads (6+ months) for thymic and senescence compounds.",
        ],
      },
      {
        id: "protocol-rules",
        eyebrow: "Cycle rules",
        title: "Measurement discipline that prevents self-deception",
        paragraphs: [
          "The biggest biohacker failure mode is correlation-as-causation across overlapping protocols. Sleep, training, supplements, and the new compound all change at once; the journal entry credits the compound. Run single-variable cycles with pre-specified endpoints and washouts. Anything else is anecdote, not data.",
        ],
        bullets: [
          "One compound per cycle; no stacking until the single-compound cycle is fully analyzed.",
          "Pre-specify your primary endpoint before starting — moving the goalpost is the most common N-of-1 failure.",
          "Wash-out periods between cycles (minimum 4 weeks) — without them you cannot distinguish residual from new effect.",
          "Hold every other variable constant (sleep, training volume, calories, caffeine) during cycles.",
        ],
      },
      {
        id: "what-to-avoid",
        eyebrow: "Safety first",
        title: "Where measurement discipline ends and safety begins",
        paragraphs: [
          "Biohacker protocols can drift into compounds with thin human data, unclear long-term risk, or active community hype that outpaces the evidence. Measurement does not substitute for safety; novelty is not signal. The compounds with the cleanest measurement infrastructure are also typically the ones with the longest human safety record.",
        ],
        bullets: [
          "Avoid compounds with no human data — animal data is hypothesis-generating, not protocol-justifying.",
          "Cancer screening before any GH-axis or growth-signaling compound — unscreened malignancies change every risk calculation.",
          "Coordinate with a clinician who can interpret your panels — solo lab interpretation produces overconfident protocols.",
          "Document side effects as carefully as effects — biohacker journals often skew toward positives.",
        ],
      },
    ],
    faqs: [
      {
        question: "Which biomarkers respond fastest to peptide protocols?",
        answer: "Inflammatory markers (hs-CRP, IL-6) often shift within 8 weeks. Epigenetic age clocks (Horvath, GrimAge) require longer windows — usually 6+ months — to register reliable changes. Cognitive batteries can detect effects within 4–8 weeks.",
      },
      {
        question: "Is epitalon worth the cost?",
        answer: "Epitalon has the most-cited preclinical longevity data of any peptide. Human evidence is limited but suggestive. Cost is modest and the cycle is short (10–20 days, 1–2× per year). Many biohackers run it as a standard annual protocol.",
      },
      {
        question: "How do peptides stack with rapamycin or metformin?",
        answer: "Most peptides have no documented interactions with rapamycin or metformin. The longevity stack pattern (low-dose rapamycin weekly, daily metformin, annual epitalon cycle) is common in biohacker communities. Coordinate with your longevity-trained clinician.",
      },
    ],
    siblings: [
      { slug: "men-over-50", title: "Peptides for Men Over 50", audience: "Men 50–59" },
      { slug: "women-over-50", title: "Peptides for Women Over 50", audience: "Women 50–59" },
      { slug: "entrepreneurs", title: "Peptides for Entrepreneurs", audience: "Entrepreneurs" },
      { slug: "veterans", title: "Peptides for Veterans", audience: "Veterans" },
    ],
    relatedGoalIds: ["anti_aging", "cognitive"],
  },
];

// ──────────────────────────────────────────────────────────────────────
// Lookups
// ──────────────────────────────────────────────────────────────────────

export function getDemographicPageBySlug(slug: string): DemographicPageData | undefined {
  return DEMOGRAPHIC_PAGES.find((p) => p.slug === slug);
}

export function getPublishedDemographicPages(): DemographicPageData[] {
  return DEMOGRAPHIC_PAGES;
}

export function getSiblingsForCluster(
  cluster: DemographicCluster,
  excludeSlug: string,
  limit = 6,
): DemographicSiblingLink[] {
  return DEMOGRAPHIC_PAGES
    .filter((p) => p.cluster === cluster && p.slug !== excludeSlug)
    .slice(0, limit)
    .map((p) => ({ slug: p.slug, title: p.h1, audience: p.audience }));
}

// ──────────────────────────────────────────────────────────────────────
// Derivation: demographic → compound recommendations
// ──────────────────────────────────────────────────────────────────────

/**
 * Pull the compound list for a (goalId × ageRange) pair.
 * Life-stage fit wins over the generic goal list when both exist.
 */
function getCompoundIdsForGoal(goalId: string, ageRange: AgeRange | null): {
  peptideIds: string[];
  lifeStageNote?: string;
} {
  if (ageRange) {
    const lifeStageFit = GOAL_LIFE_STAGE_FIT.find(
      (entry) => entry.goalId === goalId && entry.ageRange === ageRange,
    );
    if (lifeStageFit) {
      return { peptideIds: lifeStageFit.peptideIds, lifeStageNote: lifeStageFit.note };
    }
  }
  const goal = getGoalById(goalId);
  return { peptideIds: goal?.peptideIds ?? [] };
}

function buildVendorLinks(peptideId: string): VendorLink[] {
  const links: VendorLink[] = [];
  const amino = getAffiliateUrlForVendor("amino-club", peptideId);
  if (amino) {
    links.push({ vendorId: "amino-club", vendorName: "Amino Club", url: amino });
  }
  const xl = getAffiliateUrlForVendor("xl-peptides", peptideId);
  if (xl) {
    links.push({ vendorId: "xl-peptides", vendorName: "XL Peptides", url: xl });
  }
  return links;
}

/**
 * Derive one compound recommendation per priority goal.
 *
 *   - Life-stage fit (GOAL_LIFE_STAGE_FIT) takes priority over generic GOALS.
 *   - Age + sex exclusions filter the candidate list.
 *   - Age + sex cautions surface as a soft warning on the card.
 *   - Dedupe across goals so the page never recommends the same compound twice.
 *
 * Returns exactly one rec per priority goal (or zero if every candidate
 * is excluded or already taken by an earlier goal).
 */
export function derivePeptideRecs(page: DemographicPageData): DerivedPeptideRec[] {
  const used = new Set<string>();
  const recs: DerivedPeptideRec[] = [];

  for (const priority of page.priorityGoals) {
    const goal: GoalData | undefined = getGoalById(priority.goalId);
    if (!goal) continue;

    const { peptideIds, lifeStageNote } = getCompoundIdsForGoal(
      priority.goalId,
      page.ageRange,
    );

    for (const peptideId of peptideIds) {
      if (used.has(peptideId)) continue;

      // Hard exclusions (age + sex)
      if (page.ageRange && getAgeExclusionReason(peptideId, page.ageRange)) continue;
      if (page.sex !== "any" && getSexExclusionReason(peptideId, page.sex)) continue;

      const peptide = getPeptideById(peptideId);
      if (!peptide) continue;

      // Soft caution — preserved but doesn't block the rec
      const cautionFromAge =
        page.ageRange ? getAgeCautionReason(peptideId, page.ageRange) ?? undefined : undefined;
      const cautionFromSex =
        page.sex !== "any" ? getSexCautionReason(peptideId, page.sex) ?? undefined : undefined;
      const caution = cautionFromAge ?? cautionFromSex;

      used.add(peptideId);
      recs.push({
        goalId: priority.goalId,
        goalName: goal.displayName,
        framing: priority.framing,
        peptide,
        rationale: lifeStageNote ?? goal.description,
        caution,
        vendorLinks: buildVendorLinks(peptideId),
      });
      break; // top-1 per goal
    }
  }

  return recs;
}

// ──────────────────────────────────────────────────────────────────────
// Visual helpers (reused by template + JSON-LD)
// ──────────────────────────────────────────────────────────────────────

export function tierColor(tier: EvidenceTier): string {
  switch (tier) {
    case "A":   return "bg-[#0f6a52] text-white";
    case "B":   return "bg-[#0f6a52]/15 text-[#0f6a52]";
    case "B-C": return "bg-[#0f6a52]/10 text-[#0f6a52]";
    case "C":   return "bg-yellow-500/15 text-yellow-700";
    case "C-D": return "bg-yellow-500/10 text-yellow-700";
    case "D":   return "bg-stone-200 text-stone-700";
  }
}

export function riskColor(risk: RiskLevel): string {
  switch (risk) {
    case "low":      return "text-[#0f6a52]";
    case "medium":   return "text-yellow-600";
    case "med-high": return "text-orange-600";
    case "high":     return "text-orange-700";
    case "extreme":  return "text-red-600";
  }
}
